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ABSTRACT 
 
TAE EUN KIM: The Impact of Pharmacodynamic Parameters on Prediction of   
Clinical Outcome in HIV-1 infected Patients and HCV Patients with HIV co-infection 
(Under the direction of Joseph Y. Kim, Ph.D.) 
 
   The objective of this project was to use pharmacometric approaches to 
investigate the impact of in vivo pharmacodynamic (PD) parameters on clinical 
outcome in patients infected with human immunodeficiency (HIV) or hepatitis C 
(HCV) virus. Pharmacometrics is an emerging science based on developing and 
applying mathematical/statistical methods to characterize and predict 
pharmacokinetic (PK) and PD behavior, and to quantify uncertainty inherent in 
information about that behavior.  
   The degree to which viral infection is inhibited at a given antiviral drug 
concentration depends on the IC50, the concentration inhibiting replication by 50%, 
and the slope of the relationship between drug effectiveness and concentration (γ). 
In vitro experiments demonstrated that each antiretroviral (ARV) class has a 
characteristic γ associated with inhibition of HIV replication. However, whether γ is 
simply a shape factor that improves description of PK/PD data, or a fundamental 
parameter that can characterize in vivo efficacy, was not known. The first set of 
studies used integrated population PK-PD/HIV viral dynamic models to reveal that 
higher γ values are associated with better clinical outcome (larger log10 viral load 
decline; higher proportion of patients with undetectable viral load). However, the 
iv 
 
impact of γ became insignificant upon emergence of drug resistance. These studies 
also demonstrated that inclusion of γ improved PD models, although accurately 
estimating inter-individual variability in γ with a short-term monotherapy study design 
in HIV-infected patients was not possible. The second set of studies used integrated 
population PK-PD/HCV viral dynamic models to explore short-term clinical outcome 
associated with pegylated interferon (PEG-INF)-based treatment. These studies 
demonstrated no difference in γ between patients who attained sustained virologic 
response (SVR) and those who did not (NR). In contrast, estimates of IC50 and death 
rate for infected cells (δ) were significantly different between SVRs and NRs. 
Experiments also demonstrated that long-term HCV treatment outcome can be 
predicted using a population PK-PD/HCV viral dynamic model based on data 
obtained from a two-week PEG-INF-based treatment. Taken together, the results of 
this dissertation project indicate that pharmacometric approaches are useful in 
revealing the impact of in vivo PD parameters on clinical outcome in HIV and HCV 
infection.  
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CHAPTER 1 
PROJECT OVERVIEW 
 
Introduction     
Pharmacometrics, also called quantitative pharmacology, is the science of 
developing and applying mathematical and statistical methods to characterize, 
understand, and predict a drug’s pharmacokinetic (PK) and pharmacodynamic (PD) 
behavior, and to quantify uncertainty associated with information about that 
behavior. The outcome of these efforts is to pursue “knowledge-driven decision-
making” in the drug development process (Burk, Hill et al. 2008). The most important 
strength of pharmacometrics is its ability to integrate knowledge across different 
steps in the drug development process, across compounds, and across biologic 
processes. Employing these models to maximize the knowledge compiled from 
clinical trials and to plan future development experiments or steps can be a powerful 
solution to increase the efficiency of drug development and/or regulatory decisions. 
The application of pharmacometric principles to drug development can significantly 
improve decision-making and accelerate the drug development process (Johnson, 
Moore et al. 2008). The FDA also has actively promoted the role of pharmacometrics 
in the drug approval process (Chesney, Kidd et al. 2006; Plotnikoff, Karunamuni et 
al. 2008; Wang, Bhattaram et al. 2008). Modeling and simulation of data relating to 
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pharmacokinetics, pharmacodynamics, and disease progression is also a valuable 
tool to study the relationship between short-term clinical outcome and long-term 
outcome. 
   Both the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV) 
cause lifelong human infection and illness. The World Health Organization (WHO) 
reports that approximately 33.3 million persons are living with HIV infection.  In 2009, 
a total of 2.6 million persons were newly infected with HIV, and 1.8 million individuals 
died due to AIDS (http://www.who.int/hiv/data/2009_global_summary.png accessed 
in June 2011). Since the discovery of HIV-1, considerable scientific effort has paved 
the way for development of effective antiretroviral (ARV) therapy, which is now 
recognized as being a chronic and unabated life-long treatment for individuals 
infected with HIV-1. HCV infection is the most common blood-borne infection in the 
United States and a major cause of chronic liver disease worldwide. The WHO 
estimated that approximately 170 million persons, which is more than four times the 
number of persons living with HIV, are infected with HCV, with 3 ~ 4 million new 
infections each year (World Health Organization). The estimated prevalence of HCV 
seropositivity in the United States general population is 1.6 %, or 4.1 million persons 
(Armstrong, Wasley et al. 2006). Hepatitis C, which is the clinical manifestation of 
HCV infection, can be categorized into six genotypes and more than 50 subtypes, 
with genotype-1 affecting 73.7% of US patients (Alter, Kruszon-Moran et al. 1999). 
An infected person’s specific genotype is an important covariate that affects 
treatment dose, duration and response to antiretroviral therapy 
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     This project overview has been constructed to 1) review the basic biology of 
HIV and HCV infection, 2) introduce viral dynamic models in HIV and HCV infections, 
3) describe the application of population PK/PD modeling and simulation in HIV and 
HCV treatment, 4) explain how an integrated pharmacokinetic-
pharmacodynamic/viral dynamic model can be used to accelerate the development 
of drugs for HIV and HCV treatment, 5) and explain why  studying the impact of in 
vivo pharmacodynamic parameters on clinical outcome in HIV and HCV treatment is 
important.  
Basic biology of HIV and HCV infections 
   HIV is a retrovirus with a genome in the form of two copies of positive single-
stranded RNA. The main target cell of HIV is the CD4 positive T helper cell. 
Following cell entry and viral disassembly, HIV-1 RNA is translated into DNA by a 
specific viral enzyme called reverse transcriptase.  The enzyme Integrase 
translocates the viral DNA to the nucleus and leads to integration of the viral 
genome into the host genome. HIV integration usually is followed by viral 
transcription, translation, and maturation in order to generate structural and 
enzymatic proteins of the newly-created virus. However, in a certain proportion of 
infected cells, particularly in resting CD4+ T cells, HIV persists as an integrated 
proviral genome (Sierra, Kupfer et al. 2005). The mean half-life of the latent reservoir 
is very long (43.9 months), and many viruses also are capable of reactivating, 
particularly when the host cell undergoes immune stimulation (Vega-Naredo, 
Poeggeler et al. 2005). As a result, recurrent viremia occurs whenever therapy is 
discontinued, regardless of the duration of previous virologic suppression. 
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    HCV is a hepatotropic, positive-sense, single-stranded enveloped virus with a 
genome of about 9.5 kb. After HCV entry into the cell, the nucleocapsids are 
delivered to the cytoplasm, where the viral RNA acts as mRNA for translation of a 
long polyprotein. RNA-dependent RNA replication converts the positive-strand 
genome into the negative-strand copy of the genome, which serves as a template for 
the synthesis of multiple copies of the positive-strand genome for protein production. 
Cytoplasmic viral replication occurs via a membrane-associated cytoplasmic 
replicase complex, consisting of the nonstructural proteins NS3, NS4A, NS4B, 
NS5A, and NS5B. Genomic RNA-containing plasmid buds into cytoplasmic vesicles 
through intracellular membranes (Gallegos-Hernandez, Hernandez-Hernandez et al. 
2005).  
    Both HIV and HCV viruses require viral and host proteins for replication. 
However, it is important to note that HIV differs considerably in replication strategies 
compared to HCV. The HIV RNA genome undergoes reverse transcription, which 
generates  DNA that is integrated into the host genome. Therefore, HIV persists in 
infected cells, possibly for the duration of a CD4+ T-cell lifespan, even with 
successful antiretroviral therapy. On the other hand, the HCV genome is not 
converted into DNA and is not stored in the host cell nucleus. New virus copies are 
made from HCV RNA strands present in the cytoplasm of infected hepatocytes, and 
HCV RNA strands have a short half-life (3.5 days), resulting in rapid loss of viral 
genetic material by replication suppression. HCV can be cleared from the body due 
to its distinct model of replication, unlike HIV. Table 1.1 provides a summary of the 
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differences of molecular virology, viral kinetics, and drug intervention between HIV 
and HCV.  
Viral dynamic models in HIV and HCV infections 
   Over the past 15 years, the development of mathematical models and 
statistical methods has provided important quantitative insight into in vivo viral 
dynamics and drug effectiveness during the process of drug development. 
Mathematical modeling of viral dynamics was first applied for HIV using non-linear 
least squares fitting of individual patient data.  Although HIV takes approximately 10 
years from infection to cause full-blown AIDS, modeling showed the estimated 
duration of the HIV-1 life cycle in vivo was approximately 1.2 days, with the entire 
viral population being renewed every day (Ho, Neumann et al. 1995; Perelson, 
Neumann et al. 1996). Soon thereafter, a mathematical model for HCV viral 
dynamics was proposed by Neumann el al. (Neumann, Lam et al. 1998) who 
adapted a model of HIV infection for HCV. Modeling showed that viral half-life was 
short (2.7 hours on average) compared to the half-life of infected hepatocytes, which 
showed large inter-patient variability (1.7 ~ 70 days) (Neumann, Lam et al. 1998).  
   The original viral dynamic models for HIV and HCV consisted of three non-
linear ordinary differential equations (ODE) that described the change over time in 
the amount of target uninfected cell (T), infected cell (I), and free virus (V) (Figure 
1.1, Eqn. 1.1-1.3). The model was based on the Lotka-Volterra predator-prey model 
that describes the dynamics of biological systems in which a predator and its prey 
interact (Nowak and May 2000). 
6 
 
                             
VcIp
dt
dV
IdTV
dt
dI
TVTdb
dt
dT



2
1


 
Uninfected target cells (T) are assumed to be produced at a rate constant b and die 
at a rate d1.  Free virions (V) are assumed to infect uninfected cells at a rate β. 
Infected cells (I) are assumed to produce free virus at a rate p and die at a rate d2.  
This basic viral dynamic model has been developed further to models that include 
five different types of cells in order to fully describe the HIV infection (Figure 1.2) 
(Funk, Fischer et al. 2001).  This more complex model includes HIV-1-targeted CD4 
cells (T), actively-infected cells (A), latently-infected cells (L) which eventually can be 
reactivated to actively infected cells, persistently-infected cells (P) with a very long 
half-life, and defectively-infected cells (D) (Figure 1.2, Eqn. 1.4-1.9).       
                       
LdTVf
dt
dP
LaLdTVf
dt
dL
LaAdTVf
dt
dA
TdTVb
dt
dT
P
L
A




4
3
2
1




 
(Eqn. 1.1) 
(Eqn. 1.2) 
(Eqn. 1.3) 
(Eqn. 1.4) 
(Eqn. 1.5) 
(Eqn. 1.6) 
(Eqn. 1.7) 
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dt
dV
LdTVf
dt
dD
D

 5
  
 
Later modeling efforts eliminated the persistently- and defectively-infected cells from 
consideration (Rosario, Jacqmin et al. 2005; Rosario, Poland et al. 2006; Zhang, 
Kim et al. 2010) because these cells do not significantly contribute to the viral load 
changes observed during short-term clinical studies such as phase 2a HIV efficacy 
studies. However, these compartments can be important for identifying why 
complete cure has not been achieved in HIV-infected patients.  
   In HCV, the basic viral dynamic model (Figure 1.1) has been frequently used to 
describe the initial decreases of HCV RNA after treatment (Powers, Dixit et al. 2003; 
Dahari, Major et al. 2005; Talal, Ribeiro et al. 2006; Avidan, Goldstein et al. 2009). 
However, this model is not able to explain all of the observed HCV RNA profiles 
such as null response, partial response showing a flat second phase, triphasic viral 
decay, breakthrough during therapy, relapse after therapy, and most importantly, 
sustained virological response (SVR), defined as the absence of HCV RNA in serum 
at least 24 weeks after discontinuation of therapy (Zeuzem 2001). Recently, an HCV 
model that can describe SVR was proposed, with application of a concept of cure 
boundary that assumes HCV virion production should cease when all infected cell 
are cleared (Snoeck, Chanu et al. 2010). This extended model allows description of 
the long-term HCV RNA viral load profiles.    
   The early studies in viral dynamic modeling provided new knowledge about the 
dynamics and life cycle of HIV and HCV, as well as about the mode of action of 
(Eqn. 1.8) 
(Eqn. 1.9) 
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antiviral drugs.  Spurred by these findings, scientists used these models to 
understand how viral kinetics might change in response to newer forms of treatment. 
This was accomplished in part by investigating how viral kinetics differed based on 
patient covariates and by determining whether these models could be used to 
optimize therapy. Ultimately, efforts were undertaken to predict treatment outcome 
as early as possible in therapy, and to gain insight into why some groups of patients 
respond to therapy while others do not.  
Application of population PK/PD modeling and simulation in HIV and HCV 
treatment 
    Population PK/PD models can be defined as models that characterize the 
sources and correlates of variability in drug concentration and response among 
individuals who represent the target patient population receiving clinically-relevant 
doses of a drug of interest (Aarons 1991). Population pharmacokinetic modeling and 
analysis was first introduced by Sheiner et al. (Sheiner, Rosenberg et al. 1977; 
Sheiner and Beal 1980) as a means to analyze routine unbalanced, sparse 
pharmacokinetic data collected in patients. Since then, many academic, industrial, 
and regulatory scientists have contributed to the advance of population PK/PD 
modeling. Table 1.2 provides summary of the characteristics of the individual PK/PD 
and the population PK/PD approach.  
   The development of effective antiretroviral dosing regimens has been 
challenged by a lack of fundamental knowledge concerning the sources of variation 
in exposure and response to antiviral drug therapy. These sources of variation may 
be explained by factors such as inter-patient differences in genetic expression, 
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immunological response, and demographics. Population PK/PD modeling and 
simulation represent valuable methods to identify and quantify variability in exposure 
and response to antiretroviral drugs. Population pharmacokinetic  analyses reported 
across the 4 drug classes and 20 antiviral agents have been summarized in a review 
by Barrett et al. (Barrett, Labbe et al. 2005). This review article also summarized a 
list of 30 covariates explored in population PK/PD analyses of various antiretroviral 
agents, and found the most commonly-identified covariates were body weight and 
interacting drugs on clearance, body weight on volume of distribution, and postnatal 
age on clearance within pediatric populations (Barrett, Labbe et al. 2005).  Unlike 
application of population modeling and simulation in HIV treatment, its application in 
HCV treatment has not been actively reported. A recent population analysis of 
pegylated-interferon α-2a based treatment in 2100 patients with chronic hepatitis C 
infection showed that ED50, the estimated dose that results in a 50% inhibition of 
HCV viral production,  was lower in patients with HCV non-genotype 1 as compared 
with patients infected with HCV genotype 1 (Snoeck, Chanu et al. 2010).  
Use of an integrated pharmacokinetic-pharmacodynamic/viral dynamic model 
to accelerate the development of drugs in HIV and HCV treatment   
   The concept of model-based drug development has offered a quantitative 
approach to drug development decision-making by use of preclinical and available 
clinical data. In the majority of early mathematical models in HIV and HCV infection, 
treatment effects were assumed to be constant. However, in reality the effect of 
antiviral treatment changes over time. The combination of a viral dynamic model with 
drug models, such as pharmacokinetic and pharmacodynamic models, has been 
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evaluated by several authors in order to explore how time-varying drug exposure 
and drug susceptibility affect antiviral response in the context of effective dose 
selection, treatment adherence, and the emergence of resistance (Wahl and Nowak 
2000; Funk, Fischer et al. 2001; Jullien, Benhamou et al. 2005; Rosario, Jacqmin et 
al. 2005; Wu, Huang et al. 2005; Rosario, Poland et al. 2006; Shen, Peterson et al. 
2008). An integrated PK-PD/viral dynamic model showed successful prediction of 
viral load decline following short-term monotherapy with maraviroc, a CCR5 
antagonist (Rosario, Jacqmin et al. 2005; Rosario, Poland et al. 2006).  The model 
also was used to address an additional underlying pharmacologic mechanism of 
Soltegravir in order to guide a dose selection for future phase 2b study (Zhang, Kim 
et al. 2010). Two recently-approved HCV drugs, telaprevir and boceprevir, 
demonstrated the contribution of modeling and simulation during development and 
the regulatory review. Based on modeling and simulation, both products were 
approved for patient populations and at doses not directly studied in clinical trials. 
Table 1.3 provides examples of modeling and simulation applications at various 
stages of drug development in HIV and HCV 
Impact of in vivo pharmacodynamic parameters on clinical outcome in HIV and 
HCV treatment 
   The interplay between non-compliance, pharmacokinetics, disease states, and 
the drug resistance on the likelihood of virologic suppression has been intensively 
investigated. The possible impact of in vivo pharmacodynamic parameters on clinical 
outcome, however, remains to be evaluated. The degree to which viral infection is 
inhibited at any given concentration depends on the IC50 and the slope (γ) of the 
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concentration-drug effectiveness relationship, analogous to the Hill coefficient. 
Clinically, IC50 and the inhibitory quotient (IQ=Cmin/IC50) (Morse, Catanzaro et al. 
2006) are the most commonly-used parameters to compare drug potency.  Neither 
of these parameters considers the impact of γ on potency. Also, the importance of γ 
is not often considered during modeling and simulation, and its value is fixed at 1 for 
convenience (Huang, Rosenkranz et al. 2003; Rosario, Jacqmin et al. 2005; 
Rosario, Poland et al. 2006; Wu, Huang et al. 2006). Drugs with similar IC50 values, 
but larger γ values, can achieve much higher viral inhibition. Therefore, γ may be 
clinically important with regards to the impact of non-compliance and the 
development of drug resistance because γ determines the sensitivity to antiviral 
activity. In addition, a recent in vitro study (Shen, Peterson et al. 2008) demonstrated 
that each antiretroviral drug class acting through different mechanisms are 
associated with distinct values of γ; γ of all NRTIs and integrates inhibitors was 
approximately 1, γ of NNRTIs and fusion inhibitors was close to 2, while γ for 
protease inhibitors ranged from 1.8 to 4.5. The slope γ might represent the intrinsic 
characteristic of antiviral activity for each HIV drug class (Shen, Peterson et al. 
2008), but this has not been evaluated in vivo. 
   Similarly, in HCV treatment mathematical modeling has played an important 
role in understanding of HCV infection and pharmacotherapy (Rong and Perelson ; 
Powers, Dixit et al. 2003; Dixit, Layden-Almer et al. 2004; Shudo, Ribeiro et al. 
2009). Regarding the role of γ in HCV treatment, one study (Talal, Ribeiro et al. 
2006) evaluated a regimen of pegylated interferon (PEG-INF) alpha plus ribavirin. In 
HIV/HCV co-infected patients, values of γ were high (up to 4), suggesting high inter-
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subject variability for γ in this population. Importantly, the median value of γ was 
significantly higher in non-responders compared to populations with sustained 
virological response (SVR), defined as the absence of HCV RNA in serum at least 
24 weeks after discontinuation of therapy. Unlike the outcome of HIV treatment, 
HCV infection is a curable disease.  However, only approximately 50 percent of 
treated patients show SVR after a 24-week or 48-week course of combination 
therapy using PEG-INF and ribavirin (Foster and Mathurin 2008). Also, the 
effectiveness of antiviral treatment is significantly associated with patient-specific 
characteristics such as viral genotype, baseline viral load, and fibrosis grade 
(Strader, Wright et al. 2004). Therefore, it is essential to examine important 
parameters that allow one to predict SVR using short-term clinical data and further to 
identify patient-specific covariates that might be associated with such parameters. 
Project goals and objectives  
   There often is a discrepancy between in vitro and in vivo pharmacodynamic 
parameters. Studying the impact of in vivo pharmacodynamic parameters on clinical 
viral suppression and long-term clinical outcome in HIV and HCV treatment is 
challenging without the aid of mathematical models that adequately describe drug 
disposition, drug responsivity, and disease progression.  The goal of this dissertation 
project was to characterize and quantify the impact of in vivo pharmacodynamic 
parameters (IC50 and γ) on clinical outcome during HIV and HCV treatment by 
modeling and simulation with population PK-PD/viral dynamic models. Part I of this 
dissertation communicates the results of modeling and simulation studies designed 
to characterize the impact of γ associated with the in vivo concentration-response 
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relationship (as opposed to in vitro concentration-response) on the clinical outcome 
in HIV treatment. Part II is based on modeling and simulation to examine whether 
pharmacodynamic parameters recovered from short-term clinical experiments are 
associated with or predictive of HCV therapeutic outcome, and whether patient-
specific covariates or viral factors are primarily associated with inter-individual 
variability in response. In addition, the ability to use population pharmacokinetic-
pharmacodynamic/viral dynamic models developed based on short-term clinical data 
to predict long-term HCV therapeutic outcome was evaluated.  
   The current measures of antiviral clinical antiviral activity, such as IC50 and IQ, 
often neglect the concentration-response slope parameter γ. It was not well known 
whether γ is simply a shape factor that only improves the fit of a mathematical model 
to data, or whether γ is an intrinsic pharmacodynamic parameter that can 
independently characterize anti-HIV drug effectiveness. Shen L. et. al. were the first 
to address the importance of γ on the inhibitory potential of ARV drugs in in vitro 
experiments (Shen, Peterson et al. 2008). Clinically, non-compliance and drug 
resistance are the most significant cause for resurgence of previously-suppressed 
HIV-1 virus, eventually leading to ARV therapy failure. Therefore, it is critical to 
investigate the possible impact of γ on long-term clinical outcome in the context of 
drug non-compliance and resistance. In order to examine the influence of in vivo γ 
on clinical outcomes in HIV, modeling and simulation was performed using an 
integrated PK-PD/HIV viral dynamic model (Chapter 2). First, the impact of γ on viral 
load decline was evaluated by model-based simulation before collecting clinical 
data. These in silico studies allowed efficient exploration of the influence of γ on 
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clinical efficacy, taking into account non-compliance and the alteration of drug 
susceptibility due to emergence of drug resistance. Second, the impact of γ on viral 
load decline was characterized using data collected from a phase IIa short-term 
monotherapy study for an investigational Non-Nucleoside Reverse Transcriptase 
Inhibitor (NNRTI). Third, Monte Carlo simulations were conducted in order to 
investigate the impact of γ on long-term combination clinical outcomes.  
   The PEG-INF-based treatment does not result in cure in all patients who 
undergo treatment. The likelihood of response varies greatly, depending on patient-
related factors such as race, cirrhosis, age, gender and degree of liver fibrosis and 
viral factors such as viral genotype and baseline viral load. In addition, PEG-INF-
based treatment carries the risk of serious side effects. Therefore, the identification 
of clinically-validated predictors of SVR using short-term clinical data would help 
optimize anti-HCV therapy and avoid administering toxic and costly therapy to 
patients with little chance of experiencing a successful outcome. In Chapter 3, a 
population PK-PD/HCV viral dynamic model was developed in order to examine the 
predictive ability of pharmacodynamic parameters obtained from short-term clinical 
measurement of virologic outcome on SVR, and to evaluate whether patient-specific 
covariates or viral factors were associated with inter-patient variability on estimated 
parameters.  
Whether a PK-PD/HCV viral dynamic model developed from short-term clinical 
measurements is capable of predicting SVR was not known at the start of this 
project. In Chapter 4, the probability of model-predicted SVR was compared by 
Monte Carlo simulation with the observed clinical outcome in order to evaluate 
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whether the population PK-PD/HCV viral dynamic model developed from the short-
term clinical data for PEG-INF based treatment was able to reasonably predict the 
long-term clinical outcome, the percentage of patients who attain SVR. 
   Finally, the results of this research effort are discussed in the context of the 
existing literature, and suggestions for a future research agenda that will extend the 
present results are provided (Chapter 5).  
16 
 
  
Viral features HIV HCV 
Molecular virology 
Structure 
120nm; enveloped, single-stranded 
RNA virus containing two copies of its 
genome 
55-65 nm; single-stranded 
enveloped RNA genome 
Replication  
mode 
Replication occurs by transcription 
into DNA by reverse transciptase, 
translocation into the nucleus and 
integration to the host genome by 
integrase, viral transcription, 
translation, and maturation  
Replication occurs by 
synthesis of a negative-strand 
RNA intermediate within 
cytoplasmic replication 
complexes 
Integration into 
host 
chromosome 
Yes No 
Viral kinetics 
Viral half-life 5.7 hours 3.5 hours 
Viral production 10.3 x109 virions per day  1012 virions per day 
Viral decline 
patterns 
Triphasic HIV-1 RNA decline Biphasic HCV RNA decline 
Main target cell CD4 positive T helper cell Hepatocyte 
Infected cell 
half-life 
2~ > 70 days ~ 1 day 
Drug action 
Protease inhibitor inhibits the rate of 
virus production; others inhibit viral 
infection rate 
Most inhibit viral production 
rate; ribavirin results in 
uninfectious virus 
Drug intervention 
Drugs 
Triple therapy using 25 approved 
antiretrovirals in 6 classes 
Pegylated interferon (PEG-
INF) α + ribavirin (RBV) 
PEG-INF + RBV+ boceprevir 
PEG-INF + RBV+ telaprevir 
Success 
measure 
< 50 RNA copies/mL 
Undetectable virus 24 week 
after the end of treatment  
Curable? No Yes 
Treatment goal Lifelong viral suppression 
Sustained virological 
response (SVR)/Cure 
Table 1.1.: Comparison of viral features between HIV and HCV 
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Individual  PK/PD 
modeling 
Population PK/PD modeling 
Approach 
Two- stage approach 
(1) Estimating parameters for 
each patient separately 
(2) Summarizing means and 
variances of parameters 
One model explains all 
(Inter-individual variability on 
parameters is included in the 
model as a kind of parameter.) 
Data Rich data per patient 
* Sparse data, dense data, 
unbalanced data per an 
individual are all able to use. 
* Less samples per patient are 
needed (Children, cancer 
patient, etc) 
Parameter 
estimation 
method 
Least squares estimation 
Nonlinear mixed effects model 
(Maximum likelihood estimation) 
When to use 
* Single small study 
* Extensive sampling 
* Homogeneous population 
* Non-compartmental data 
analysis 
* Obtaining initial values of 
parameter estimates for 
further population analysis 
* Combining the result of several 
different studies (meta-analysis) 
to capture overall effects 
* Not enough data per subject 
* Loss of balance due to the   
varying amount of data per 
subject 
*quantifying measurable and 
unexplainable sources of 
variability 
* Understanding factors leading 
to variability in PK/PD for 
appropriate drug use and trial 
design 
 
  
Table 1.2.: Summary of the characteristics of the individual PK/PD and the 
population PK/PD approach 
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Disease Drugs M&S applications References 
HIV Maraviroc 
 Population PK-PD/HIV viral 
dynamic model to support design 
decisions for a monotherapy study 
using various dosing regimens of 
maraviroc given with and without 
food for optimizing phase 2a study 
 Population pharmacokinetic (PK)–
pharmacodynamic (PD) model that 
describes CCR5 receptor 
occupancy by maraviroc after oral 
administration at different doses 
and to assess the relevance of 
receptor occupancy  
(Rosario, Jacqmin 
et al. 2005; 
Rosario, Poland 
et al. 2006) 
 
 
 
 
(Rosario, Jacqmin 
et al. 2008) 
HIV 
 
Soltegravir 
 
 Population PK-viral dynamic model 
to characterize the relationship 
between plasma concentrations and 
HIV viral decline in HIV-infected 
patients for guiding dose selection 
for future phase 2b study 
 
(Zhang, Kim et al. 
2010) 
HCV Telaprevir 
 Second-phase hepatitis C virus 
RNA decline during telaprevir-
based therapy increases with drug 
effectiveness: implications for 
treatment duration 
 A multi-variant viral dynamic to 
quantify the evolution and in vivo 
fitness of variants in subjects dosed 
with monotherapy 
 Probabilistic and viral dynamic 
models to show rapid emergence of 
protease inhibitor resistance in 
hepatitis C virus 
(Guedj and 
Perelson 2011) 
 
 
 
(Adiwijaya, 
Herrmann et al. 
2010) 
 
 
(Rong, Dahari et 
al. 2010) 
HCV 
Boceprevir 
 
 Estimation of relative viral fitness 
based on a multiple variant viral 
kinetic model to characterize of 
resistance to boceprevir  
 
(Susser, Welsch 
et al. 2009) 
  
Table 1.3.: Examples of modeling and simulation applications at various stages 
of drug development in HIV and HCV 
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Figure 1.1.: Basic model used to study the viral dynamics of HIV and HCV; 
adapted from (Layden, Layden et al. 2003).  
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Figure 1.2.: The HIV viral dynamic model that can be used for modeling and 
simulation for long-term clinical outcomes; adapted from (Funk, Fischer et al. 
2001). 
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CHAPTER 2 
USE OF A POPULATION PHARMACOKINETIC-PHARMACODYNAMIC/HIV 
VIRAL DYNAMIC MODEL TO EXAMINE THE IMPACT OF THE IN VIVO SLOPE 
PARAMETER FROM CONCENTRATION-RESPONSE ANALYSIS ON CLINICAL 
OUTCOME FOLLOWING HIV TREATMENT 
 
SUMMARY 
 
     The current measures of antiviral clinical antiviral activity such as IC50 and IQ 
often neglect the concentration-response curve slope parameter γ. It was not well 
known whether γ is a shape factor that only improves the mathematical fit or whether 
γ is a pharmacodynamic parameter that can independently characterize anti-HIV 
drug effectiveness. In the present study, we investigated the impact of in vivo slope 
parameter γ of concentration-response on the clinical outcome in HIV treatment. At 
first, the impact of γ on viral load decline was evaluated by model-based simulation 
before collecting clinical data. These in silico studies allowed efficient exploration of 
the influence of the γ on clinical efficacy taking into account non-compliance and the 
alteration of drug susceptibility due to the emergence of drug resistance. Secondly, 
the impact of γ on viral load decline was characterized using data collected from a 
phase IIa short-term monotherapy study for an investigational Non-Nucleoside 
Reverse Transcriptase Inhibitor (NNRTI) drug. Lastly, Monte Carlo simulation was 
conducted in order to investigate the impact of γ on long-term combination clinical 
26 
 
outcomes. In these studies, we revealed that higher γ can contribute to achieve 
better clinical outcomes such as the larger log10 viral load decline from baseline or 
higher proportion of patients who attain undetectable viral loads in short-term and 
long-term clinical simulation studies, respectively. However, the impact of γ is 
insignificant once the emergence of drug resistance in those studies. We also 
provided an insight that the addition of γ to PD model improves model fitting, but it 
was impossible to accurately estimate inter-individual variability of γ with the current 
short-term monotherapy clinical study design in HIV infection in order to associate 
the influence of γ with clinical outcomes. 
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INTRODUCTION 
 Ideally, in vitro antiviral activity associated with clinically relevant-concentrations 
would guide drug development and the selection of dosage regimens that maximally 
suppress viral replication. The relationship between antiretroviral (ARV) drug 
effectiveness on viral replication and drug concentration is sigmoidal, with the 
degree of inhibition at a given drug concentration dependent on the IC50 and the 
slope parameter γ (Figure 2.1). IC50, the concentration that mediates 50% of the 
maximum inhibitory effect, is widely used to compare drug potency among ARV 
drugs and to measure virus susceptibility through the fold change in drug resistance 
compared with wild type virus. γ is a parameter that determines the shape of  the 
effectiveness vs. concentration profile, and also may be indicative of cooperativity in 
the binding of multiple drug ligands to linked binding sites (Hill 1910).  
 
 Whether γ is a shape factor that only improves the mathematical fit of a model to 
the data or a more fundamental pharmacodynamic parameter that can 
independently characterize ARV drug effectiveness has not been established. Shen 
et. al. first addressed the importance of γ on the inhibitory potential of ARV drugs in 
in vitro experiments (Shen, Peterson et al. 2008). ARV drugs available for treating 
patients with HIV-1 infection are classified into five classes based on target site at 
different stages of the viral life cycle: nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI), fusion inhibitors (FI), and integrase inhibitors (II) (Sun, Zhou et al. 2003). 
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Shen’s group demonstrated that each ARV drug class has a characteristic γ from the 
in vitro dose-response curve: NRTIs and IIs have slopes of ~1 while NNRTIs, FIs 
has slopes of ~2, and PIs have sloped between 1.81 and 4.53. However, the 
influence of γ on the in vivo response to ARV drugs has not been explored.  
 
 There is a discrepancy in the pharmacodynamic measures of ARV drugs 
between   in vitro experiments and clinical studies when characterizing the 
relationship between ARV response and drug concentrations. Unlike in vitro 
experiments, the percent of viral inhibition cannot be measured directly in clinical 
studies, and instead decreases in viral load from the baseline are measured as a 
surrogate to assess the response to ARV drugs. In order to examine the influence of 
in vivo γ on antiviral activity, an integrated pharmacokinetic (PK)-pharmacodynamic 
(PD)/HIV viral dynamics model (Figure 2.2) is a valuable tool. An HIV viral dynamic 
model is a mathematical model that characterizes simultaneously viral dynamics in 
different compartments of uninfected CD4+ T cells and HIV-1-infected cells. These 
cellular populations include actively-infected cells, latently-infected resting cells, 
persistently-infected cells, and cells harboring defective provirus (Hawwa, Millership 
et al. 2008; Rong and Perelson 2009). In this integrated approach, a 
pharmacodynamic model links the pharmacokinetic model to the HIV viral dynamic 
model, allowing characterization of viral inhibition fraction as a function of time. The 
integrated PK-PD/HIV viral dynamic model has been shown to predict successfully 
decreases in viral load following short-term monotherapy with maraviroc, a CCR5 
antagonist (Rosario, Jacqmin et al. 2005; Rosario, Poland et al. 2006). The use of 
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integrated PK-PD/HIV viral dynamic models has increased during new anti-HIV-1 
drug development. 
 
 An initial ARV regimen generally consists of two NRTIs in combination with an 
NNRTI, a PI (preferably boosted with ritonavir), or an integrase inhibitor . In clinical 
trials, NNRTI-, PI-, Integrase inhibitor-based regimens have all resulted in HIV RNA 
decreases in a large majority of patients (Squires, Lazzarin et al. 2004; Riddler, 
Haubrich et al. 2008; Lennox, DeJesus et al. 2009), but clinical outcomes according 
to various patterns of compliance and drug resistance are not fully understood. 
Despite the relative lack of empirical data, it is safe to speculate that the forgiveness 
of various ARV treatment strategies may differ depending on the different PK-PD 
characteristics of these drugs. It might be expected that ARV regimen efficacy would 
vary over time if drug exposure and viral susceptibility changes over time. 
Compliance (Paterson, Swindells et al. 2000; Ferguson, Donnelly et al. 2005; Levine, 
Hinkin et al. 2005; Chesney 2006; Gulick 2006) and drug resistance (Little, Holte et 
al. 2002; Johnson, Li et al. 2008) are the most significant causes for the resurgence 
of HIV-1 virus eventually leading to ARV therapy failure (Bangsberg, Moss et al. 
2004; Braithwaite, Shechter et al. 2006). It remains to be evaluated how the new 
finding by Shen et al. (Shen, Peterson et al. 2008) could affect long-term clinical 
outcomes, especially with regards to drug compliance and resistance development.  
 
 In order to examine the influence of in vivo γ on clinical outcome, the present 
study utilized a modeling and simulation strategy with an integrated PK-PD/HIV viral 
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dynamic model. First, the impact of γ on viral load decline was evaluated by model-
based simulation. This in silico study allowed efficient exploration of the influence of 
the γ on clinical efficacy, including consideration of non-compliance and the 
alteration of drug susceptibility due to the emergence of drug resistance. Second, to 
the feasibility of accurate estimation of γ based on clinical ARV data was explored, 
together with further evaluation of the impact of γ on the viral load decline during 
short-term monotherapy for HIV-1 infection. Third, Monte Carlo simulations were 
conducted in order to investigate the impact of γ on the clinical outcomes expected 
from long-term combination therapy.  
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METHODS 
 In order to evaluate the impact of γ on clinical outcome, modeling and simulation 
using an integrated PK-PD/HIV viral dynamic model was applied in three steps as 
follows: 
Step 1: (Learning phase). Before collecting clinical data, the impact of γ on the rate 
of viral decay and the log10 change from the baseline in HIV-1 RNA on the last day 
of treatment was evaluated.  
Step 2: (Confirmatory phase). The impact of γ on viral load decline using data from a 
phase IIa short-term monotherapy study for an investigational Non-Nucleoside 
Reverse Transcriptase Inhibitor (NNRTI) drug was characterized.  
Step 3: (Simulation study). Monte Carlo simulation was performed in order to 
evaluate the possible impact of γ on the long-term clinical outcome in combination 
therapy (Atripla®, efavirenz/emtricitabine/tenofovir).  
 All population pharmacokinetic and sequential PK-PD/HIV viral dynamic 
modeling for short-term clinical studies and Monte Carlo stochastic simulations for 
long-term clinical trials were conducted using non-linear mixed-effects models as 
implemented in the NONMEM computer program (version 7.1.2, ICON Development 
Solutions, Hanover, MD) in conjunction with Compaq Visual Fortran. Compliance 
model simulations, data processing and graphical analyses were carried out using R 
(version 2.12.2, http://www.r-project.org). Deterministic long-term clinical outcome 
simulations were performed using Berkeley Madonna (Version 8.3.18) (Koblin, 
Husnik et al. 2006).  
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Step 1: In silico study to compare simulated decreases in viral load associated 
with ARV monotherapy for five hypothetical drugs with different γ values  
    A 10-day monotherapy study for an efavirenz (EFV)-like drug with 100% 
compliance and a 29-day monotherapy study for the same drug with possible 
noncompliance were simulated to investigate the effect of γ on viral load with 
consideration of viral susceptibility. The scheme of models used for this simulation 
was illustrated in Figure 2.2.   
Compliance model:  
    A 2-state Markov model was used to describe the probability of missing a dose.  
Table 2.1 lists the transition probabilities for this model. Each probability P i Æ j 
corresponds to the probability of taking dose ‘j’ if the previous dose was ‘i’. Variable 
timing in dose intake was simulated using a normal distribution with a mean of 24 h 
and a standard deviation of 4 h (Table 2.1.).  
PK/PD model: 
    Drug concentrations were simulated using a one-compartment model with first 
order absorption and elimination with a fixed set of pharmacokinetic parameter 
values (Eqn. 2.1, Table 2.1.) and dose administration times. The concentration-time 
profiles for 100 subjects were simulated using 20% inter-individual variability on all 
pharmacokinetic parameters. Antiviral activity was simulated with a sigmoidal Emax 
model to express viral inhibition fraction INH (t) at each simulated plasma 
concentration (Eqn. 2.2). For low and high viral susceptibility, values of IQ, the ratio 
between Ctrough and IC50, were set to 0.5 and 5, respectively. The range of γ values 
was 1 to 5 as reported in a previous in vitro study (Shen, Peterson et al. 2008).   
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HIV viral dynamic model: 
 Time-varying viral inhibition enters the predator-prey viral dynamics model by a 
factor of (1-INH(t)). The adapted viral dynamic model (Hawwa, Millership et al. 2008) 
used in this simulation study is illustrated in Figure 2.2 and model parameters are 
defined in Table 2.1. Of note, the model excluded two compartments, persistently-
infected CD4+ cells and defectively-infected CD4+ cells, as these compartments are 
useful for long-term viral suppression under therapy. It was assumed that a drug 
acts by reducing the viral infectivity rate constant (β) by the INH(t) factor. During 
treatment, the following equations are relevant: 
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where T(t), A(t), L(t) and V(t)  denote target uninfected CD4+ cells, actively virus-
producing cells, latently infected cells and free HIV-1 viruses, respectively. 
Step 2: Characterizing the impact of γ on viral load decline using a phase IIa short-
term monotherapy study for an investigational Non-Nucleoside Reverse 
Transcriptase Inhibitor (NNRTI) drug.   
   In the present study, it was hypothesized that IC50 and γ may be related to viral 
suppression. In specific, individuals with higher values of γ would show higher viral 
load decline on the last treatment day. Plasma concentration and viral load data 
were obtained from an investigational NNRTI drug Phase IIa short-term 
monotherapy, consisting of 7 days of drug administration (between 30 and 800 mg 
QD) in 48 HIV-1 infected NNRTI-naïve patients. Blood samples for determining drug 
concentrations in order to characterize pharmacokinetics were obtained prior to the 
first dose, and on treatment days 1 and 7 when intensive sampling was conducted. 
Blood samples for determining viral load were collected daily (Figure 2.5.). 
 Throughout the model-building process, the following criteria were used to 
assess model performance: observed vs. predicted plots, plots of residuals vs. 
model predictions and time, objective function values and parameter precision 
(relative standard errors, RSEs).  Likelihood ratio test (LRT) was used to compare 
goodness-of-fit between competing two models for the same dataset; a decrease in 
the objective function value of at least 3.84 (χ2 distribution with 1 degree of freedom 
for P < 0.05) relative to the base pharmacokinetic model was required for addition of 
a single fixed-effect parameter under LRT. The final model was validated using the 
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visual predictive check (VPC) technique, the procedure for which was as follows. A 
total of 1000 replications of the data were simulated using the final model, and 5th 
and 95th percentiles of the simulated concentration-response intervals were 
computed, yielding a 90% simulation interval (SI). Model performance was evaluated 
based on upon the extent to which the observed values fell within the associated SI.  
Post-hoc parameter estimates from the final pharmacokinetic model were utilized 
in the viral dynamic model to derive the predicted plasma concentration vs. time 
profile for each individual. The adapted viral dynamic model (Eqn.2.3 – Eqn.2.6) 
used in modeling and simulation is illustrated schematically in Figure 2.2, and model 
parameters are defined in Table 2.2. Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) inhibit the transcription of viral RNA to DNA, thereby reducing the viral 
infectivity constant (β). The inhibition of β by the study drug was modeled using a 
sigmoidal Emax model (Eqn.2.2). The sequential population PK-PD/viral dynamic 
model was fit to the HIV-1 RNA data to estimate viral life cycle parameters and 
pharmacodynamic parameters. Two models, model 1 (including only in vivo IC50 as 
a single pharmacodynamic parameter) and model 2 (including in vivo IC50 and in 
vivo γ) were used in order to investigate the possibility of accurately estimating γ 
from a monotherapy study used during HIV-1 drug development, and the possible 
impact of γ on the viral load decline on day 8 from baseline. In the viral dynamic 
model, R0 (basic reproductive ratio) and δ (rate of death of actively-infected cells) 
were estimated while the remaining parameters were fixed to literature values (Table 
2.1.) The baseline log10-viral load (Log V0) was modeled as a linear function of the 
observed baseline value, with a normally-distributed random effect (η) to account for 
36 
 
imperfect measurement of this quantity: Log V0 (estimate)=Log V0 (observation) + η. Data 
analysis was performed in NONMEM using subroutine ADVAN6, with the first-order 
conditional estimation (FOCE) determined by the interaction method.  
Step 3: Monte Carlo simulation in order to evaluate the possible impact of γ on 
the long-term clinical outcome associated with the combination regimen of 
Atripla. 
   Atripla is a combination of efavirenz (EFV)/emtricitabine (FTC)/tenofovir 
disoproxil fumarate (TDF) at doses of 600mg/200mg/300mg. Atripla was the first 
fixed-dose triple antiretroviral combination tablet available for once-daily single-tablet 
regimen, and was used as a case regimen of HIV combination therapy in this 
simulation study. The sequential population PK-PD/HIV viral dynamic model used for 
this simulation study is illustrated in Figure 2.8, and model parameter estimates used 
are defined in Table 2.3. Drug concentrations were simulated using published 
population pharmacokinetic models (Eqn.2.7 – Eqn.2.14) for EFV (Csajka, Marzolini 
et al. 2003), FTC (Hirt, Urien et al. 2009) and TDF (Gagnieu, Barkil et al. 2008). No 
clinically-significant pharmacokinetic interactions among EFV, FTC and TDF have 
been observed (Deeks and Perry 2010). Based on in vitro evidence, it was assumed 
that the combined effects of two drugs (FTC and TDF) from the same ARV class 
(NRTI) were additive, while the combined effects of drugs from different ARV 
classes were multiplicative (Feng, Ly et al. 2009; Huang, Qu et al. 2010). The 
pharmacodynamic models for EFV effect, additive effect between FTC and TDF, and 
total effect for all three drugs were described in Eqn.2.15, Eqn. 2.16, Eqn. 2.17, 
respectively. The values of in vivo IC50 for these three drugs are currently unknown. 
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Therefore, the deterministic simulation for the sequential PK-PD/HIV viral dynamic 
model for Atripla was performed using estimates within the range of in vitro IC50 
values (Table 2.3.) in wild-type viruses for each drug obtained from Atripla insert 
package in order to get insight of in vivo IC50 value of each drug.  
    A full HIV dynamic model characterizing four different types of infected cells 
such as actively-infected cell (A), latently-infected resting cells (L), persistently-
infected cells (P) and defectively-infected cells (D) (Hawwa, Millership et al. 2008) 
for long-term clinical outcome was used (Figure 2.8, Eqn.2.18 – Eqn. 2.23).  
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Before evaluating the impact of γ on long-term clinical outcome, the integrated 
population PK-PD/HIV viral dynamic model was validated by comparing the 
simulated percentage of patients with < 50 HIV-1 RNA copies/mL at 48 week with 
clinical observations for patients receiving Atripla treatment (Dejesus, Young et al. 
2009; Peng, Pai et al. 2010; Rong, Nielsen et al. 2010; Tong, Fang et al. 2010). In 
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this validation step, the probability distribution of patients (%) with HIV-1 RNA <50 
copies/ ml at week 48 were generated in 100 simulation trials using the model 
(displayed schematically in Figure 2.8) with a dataset including hypothetical 1000 
subjects. This stochastic Monte Carlo simulation was performed based on reported 
values for variance (ω2) of inter-individual variability on pharmacokinetic parameters 
for EFV, FTC and TDF (Table 2.3.). 
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where i, j, and k are the number of individuals (i=1,2,3…..100), time points 
(j=0,……48 weeks) and simulation trials (k=1,2,3…. 100), respectively. F1_EFVi, 
Ka_FTCi, CL_FTCi, CL_TDFi, Vd_TDFi are simulated bioavailability for EFV, rate of 
absorption for FTC, clearance for FTC, clearance for TDF, the volume of distribution 
for TDF, respectively, for individual i, θµ is the mean value of parameters, ηi is the 
deviation of the ith individual from mean values of those parameters (θµ). The 
(Eqn. 2.24) 
(Eqn. 2.25) 
(Eqn. 2.26) 
(Eqn. 2.27) 
(Eqn. 2.28) 
(Eqn. 2.29) 
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individual simulated concentrations for each drugs using (Eqn. 2.24 – Eqn.2.29) 
were used for individual simulated HIV viral load measurement (Vi,j,k) for 100 
simulation trials. The variance of residual was assumed to be 0.01 copies/mL.  
    Once the model was validated, the percentage of patients with < 50 HIV-1 RNA 
copies/mL at Week 48 was investigated using different values of γ in the sigmoid 
Emax model of the PK-PD/HIV viral dynamic model in order to examine the impact of 
γ on long-term clinical outcome. In addition, the influence of γ on long-term clinical 
outcome was evaluated under consideration of various patterns of compliance and 
drug resistance of Atripla treatment.  
    The compliance of patients with Atripla therapy was simulated with a 2-state 
Markov model as described earlier. There are 5 potential categories of resistance 
patterns for the combination therapy of EFV, FTC and TDF: (1) EFV resistance 
appearing without FTC/TDF resistance, (2) EFV resistance appearing before 
FTC/TDF resistance, (3) EFV resistance appearing simultaneously with FTC/TDF 
resistance, (4) EFV resistance appearing after FTC/TDF resistance, and (5) 
FTC/TDF resistance appearing without EFV resistance. Clinical observations have 
indicated that resistance to FTC + TDF + EFV was associated primarily with NNRTI-
resistance development (McColl DJ. Nov 17-20, 2005. Dublin. Ireland.). In the 
curtent simulation scenario (drug resistance to Atripla treatment), an observed 
example case for EFV resistance appearing without FTC/TDF resistance (Miller 
June 8-12, 2010. Dubrovnik. Croatia. Abstract 3. ) was considered. In this example 
case, a patient experienced EFV resistance due to the emergence of K103N 
resistance mutation without FTC resistance for approximately 20 weeks. To mimic 
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the change in IC50 for EFV over time due to the development of drug resistance, the 
IC50 for EFV was described by Eqn. 2.30.  
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where IC50_max_EFV is the maximum IC50 for EFV (40-fold higher than the IC50 against 
wild-type virus in this example case) and ta is the accumulation time scale for IC50 
until the maximum IC50 is reached.  All simulations were performed using Berkeley 
Madonna (Version 8.3.18). 
(Eqn. 2.30) 
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RESULTS 
    The impact of γ on clinical outcome was characterized by modeling and 
simulation with a PK-PD/HIV viral dynamic model. The in silico study, which was 
performed before collecting clinical data, showed that at low viral susceptibility (IQ = 
0.5) those drugs with higher values of γ are much more sensitive to the change of 
drug concentration (Figure 2.3 B.1). Therefore, those drugs with γ of 1, which are 
less sensitive to changes in concentration, contribute to the greatest effect on viral 
load decline on the last treatment day (Figure 2.3 B.2). Alternatively, at an IQ of 5, 
the fraction of sustained inhibition exceeded 80% regardless of the values of γ 
(Figure 2.3 C.1) and drugs with γ of 1 showed the smallest impact on the viral load 
decline (Figure 2.3 C.2). This observation also implies that there is no significant 
difference in viral load decline among drugs with values of γ greater than or equal to 
2, but there is a large change on viral load decline between γ values of 1 and 2 
(Figure 2.3 B.2 & C.2) These results are consistent with the hypothesis that γ affects 
both the log10 change in HIV-1 RNA on the last treatment day and the rate of viral 
decay on short-term monotherapy studies; a higher value of γ results in a larger log10 
change in HIV-1 RNA and a more rapid reduction in HIV-1 RNA when the HIV virus 
is susceptible to the drug. However, once the drug effectiveness decreases,  smaller 
values of γ produce larger declines in viral load. 
    The influence of γ on viral load in the presence of variable drug exposure due 
to non-compliance at low and high drug susceptibility was examined (Figure 2.4). 
Varying the simulated pattern of non-compliance allowed for characterization of drug 
holidays (Figure 2.4 A) and variability in dose times (Figure 2.4 B). A low γ value 
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resulted in a slower rate of viral rebound compared to values of γ >= 2 at IQ of 0.5 
(Figure 2.4 C.2). At IQ of 5, a low γ caused a smaller viral load decline, while higher 
values of γ maintained viral inhibition despite a large fluctuation of drug exposure 
due to non-compliance (Figure 2.4 D.2). Regardless of drug susceptibility, there was 
no significant difference in viral rebound for drug with γ >= 2.  
    The in vivo γ was estimated from a population PK-PD/HIV viral dynamic model 
based upon a phase IIa short-term monotherapy study for an investigational NNRTI 
drug. The goodness-of-fit assessment revealed that the viral-load profiles were well-
described by the final model (model 1) without systematic bias (Figure 2.6). Table 
2.2 provides a comparison of parameter estimates between model 1 (including only 
IC50) and model 2 (including both IC50 and γ). Including two more parameters, the 
population mean and inter-individual variability of γ, reduced the OFV by 
approximately 10. The population estimate of γ was 0.92, and the inter-individual 
variability for γ was high (97%). In contrast, inter-individual variability on IC50 was 
reduced from 141.8% to 68.4% when adding γ into model 1.  
 The association between either IC50 or γ and viral load decline from baseline on 
day 8 was evaluated with model 1 and model 2 (Figure 2.7). IC50 estimated from 
model 1 could not appropriately characterize the relationship of drug effect with viral 
load decline (Figure 2.7 A); low IC50s of two individuals (ID #43 and #47) were 
estimated, although these individuals showed poor efficacy with evidence of low viral 
load decline from baseline to the last treatment day (< 1 log10 copies/ml). A very high 
IC50 was estimated for ID #3, who showed good efficacy with a viral load decline of 
1.5 log10 copies/ml. These observations suggested that IC50 alone cannot 
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appropriately describe the drug effect based only upon clinical observations. 
However, IC50  and γ as estimated from model 2 showed a strong relationship with 
viral load declines, and the high IC50 estimates for the poor responders (ID #43 and 
#47) were rectified (Figure 2.7, B.1 & B.2). After excluding these two poor drug 
responders, linear regression analysis indicated significant relationships between γ 
and viral load decline as well as between IC50 and viral load decline; individuals with 
higher values of γ evidenced a larger viral load decline on day 8 (P < 0.001), while 
the lower IC50 resulted in the larger viral load declines (P=0.01) (Figure 2.7, B.3 & 
B.4).  
    The possible impact of γ on long-term clinical outcome associated with the 
combination regimen of Atripla (EFV+FTC+TDF) was evaluated by Monte Carlo 
simulation using a PK-PD/HIV viral dynamic model (Figure 2.8). The simulated 
concentration-time profiles for each of the three drugs, as determined through the 
use of previously-reported model structures and parameter values (Table 2.3), were 
compatible with observed concentration-time profiles (Figure 2.9). In addition, the 
probability distribution for patients (%) with HIV-1 RNA <50 copies/ml at week 48, 
performed by 100 trial simulations using a population PK-PD/HIV viral dynamic 
model with a dataset including 1000 subjects,  ranged between 89% and 94 % 
(Figure 2.10 A), which corresponded to clinical observations  (Deeks and Perry 
2010).  This simulation analysis also showed that the proportion of patients with an 
undetectable viral load reached a maximum at approximately week 8 (Figure 2.10 B), 
which was in agreement with clinical observations (Gallant, DeJesus et al. 2006).  
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    Once the model was validated with clinical observations, the impact of γ on the 
outcome from the long-term combination regimen of Atripla was evaluated. In this 
simulation, higher values of γ significantly improved the proportion of patients with 
undetectable viral loads: 92% vs. 100% for γ values of 1 and 2, respectively (Figure 
2.11). However, all 1000 virtual subjects in this simulation experienced viral rebound 
at approximately week 5, even with higher γ, under a scenario of drug resistance 
development (Figure 2.12). The simulation of compliance for the fixed-dose triple 
antiretroviral combination tablet, Atripla (EFV/FTC/TDF), was able to describe 
irregular dosing times and missing doses (Figure 2.13). Under the scenario of non-
compliance, log10 HIV-1 RNA-time profiles generated by Monte Carlo simulation 
(n=1000) using a population PK-PD/HIV viral dynamic model were evaluated with 
different values of γ for EFV. These simulations showed that γ values of 1.5 and 2 
resulted in faster undetectable log10 HIV-1  compared with that for γ of 1 (week 3 vs. 
week 4.5) (Figure 2.14). In addition, the median time for viral rebound was also 
shorter for higher γ, occurring at week 4.2, 6 and 8 for γ of 1, 1.5 and 2, respectively 
(Figure 2.14). Under both scenarios of non-compliance and the development of drug 
resistance, a shorter time to reach undetectable log10 HIV-1 RNA  was observed for 
higher γ values, but eventually all 1000 virtual subjects experienced viral rebound 
with no difference in the time to viral rebound  among values of γ (Figure 2.15). 
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DISCUSSION  
  The significance of γ has been reported as a critical missing dimension in 
the evaluation of the activity of ARV drugs in in vitro experiments (Shen, Peterson et 
al. 2008; Shen, Rabi et al. 2009). The impact of γ on clinical outcome also has not 
been characterized previously due to difficulty in obtaining direct measurement of γ 
based on clinical data. The objectives of the present study were (1) to determine the 
impact of the in vivo slope parameter (γ) on clinical outcome by examining the log10 
change from the baseline in HIV-1 RNA on the last day of treatment, (2) to 
characterize the impact of γ on viral load decline using a phase IIa short-term 
monotherapy study for an investigational NNRTI drug, and (3) to evaluate the 
possible impact of γ on the long-term clinical outcome in combination therapy with 
Atripla (EFV+FTC+TDF).  
   Higher values of γ resulted in larger decreases in log10 HIV-1 RNA for 
scenarios in which the HIV virus was susceptible to the drug (Figure 2.3. C.2). 
However, once drug effectiveness decreased due to development of drug 
resistance, smaller values of γ produced a larger decrease in viral load (Figure 2.3 
B.2). The opposite effect of γ on log10 change in HIV-1 RNA based on susceptibility 
to HIV virus can be explained by the area under the curve (AUC) for the 
effectiveness vs. time profile. In the emergence of drug resistance, in which IC50 
increases and IQ decreases, higher γ values result in enhanced sensitivity to 
changes in drug concentrations (Figure 2.3. B.1) resulting in a smaller AUC of the 
effectiveness-time profile and smaller log10 change in HIV-1 RNA from the baseline.  
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 Results of the present study also showed that the inclusion of γ does not only 
improve the correspondence of the model to the data, but also appropriately relates 
the pharmacodynamic parameters to the log10 change from baseline. The log10 
change from baseline is the most frequently-used surrogate marker in phase IIa 
short-term monotherapy studies; the proportional relationship between γ and log10 
change from baseline, and the disproportional relationship between IC50 and log10 
change from baseline, were noteworthy.  In contrast, IC50 alone as a 
pharmacodynamics parameter was not able to appropriately describe the drug effect 
on the log10 change from baseline (Figure 2.7). However, evidence from the visual 
predictive check simulation and bootstrap failed for model 2 (containing both IC50 
and γ), and the objective function values for the addition of a parameter for random 
effect on γ was not statistically significant. The interpretation of these results is that γ 
would not be able to accurately estimate with the current clinical study design for 
measurement of pharmacokinetic and viral loads in a phase IIa short-term 
monotherapy study. This particular challenge result can be explained by the lack of 
clinical data (viral load) for response-time per concentration-time profile in order to 
accurately estimate γ, the shape parameter of drug exposure-response curve. In the 
typical clinical study, concentrations and viral loads are collected over time scales of 
hours and days, respectively, while in vitro study designs allow both concentration 
and direct drug response (% inhibition) to be collected over a time scale of hours.  
   This study also demonstrated that higher values of γ contribute to better 
long-term clinical outcome (Figure 2.11). Despite the improved response to drug 
therapy, all virtual subjects with γ values of either 1 or 2 experienced viral rebound.  
48 
 
Regardless of the value of γ, development of drug resistance will occur, and 
resistance becomes the dominant phenomenon in determining the eventual clinical 
outcome during HIV therapy (Figure 2.12). The reason that γ has little impact on the 
long-term clinical outcome when emergence of drug resistance occurs is that the 
fold-change in IC50 is significantly larger than the fold-change in γ. When accounting 
for non-compliance, higher values of γ contribute to faster time to achieve 
undetectable viral loads: 4.5, 3.2 and 2.8 week for 1, 1.5 and 2 of γ, respectively 
(Figure 2.14). Higher γ values also result in longer viral suppression at undetectable 
levels. These results lend further credence to the suggestion that γ might influence 
clinical outcome because antiviral activity is affected by γ in addition to IC50 and drug 
concentration. However, the contribution of γ appears to be insignificant once the 
development of drug resistance occurs (Figure 2.15).  
   In conclusion, the importance of γ has been addressed previously in the in 
vitro setting (Shen, Peterson et al. 2008; Shen, Rabi et al. 2009; Shen and Siliciano 
2010). The present study demonstrated that higher values of γ can contribute to 
improved apparent outcome during in both short-term and long-term clinical studies. 
However, the impact of γ becomes insignificant once the emergence of drug 
resistance occurs.  
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Compliance 
model Distribution 
Dose interval (hr) 
Mean         SD 
  
   P0->0     P0->1                    0.6     0.4 
                           =  
   P1->0     P1->1                    0.2     0.8 
 
24                4 
   
PK parameters PD parameters 
PK/PD model 
CL (L/hr)    Vd(L)   Ka (hr-1) Emax    IC50 at IQ=0.5 or 5 
Drug (600mg) 10          173        1.39 1         2.48,  0.248 
   
Viral dynamic 
model  Biologic interpretation Values 
b (cell/mL·hr) Birth rate of uninfected CD4+ cells 0.0259 
d1 (hr-1) Death rate of uninfected CD4+ cells 0.00025 
d2 (hr-1) Death rate of actively virus-producing CD4+ cells 0.028 
d3 (hr-1) Death rate of latently infected cells 0.00055 
a (hr-1) Activation rate of latently infected cells 0.00154 
R0 Reproductive ratio before treatment 7.39 
p/c Ratio of birth to death rate of virus 35.4 
fA 
Fraction of newly infected cells that 
become actively infected cells 0.97 
fL 
Fraction of newly infected cells that 
become latently infected cells 0.029 
 
 
 
 
 
 
 
Table 2.1.: Parameter values used in in silico study (step 1) in order to compare 
simulated viral load declines of ARV monotherapy of five hypothetical drugs with 
different γ values; values for viral dynamic system were taken from the publication 
(Funk, Fischer et al. 2001). 
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Model 1 Model 2 
Parameter 
 Estimate    1RSE(%)      Estimates        RSE(%) 
 
Fixed effect (population mean) 
 IC50 (ng/L)                              82.70            (30.1)                75.50                 (31.5) 
 γ                                             NA                                         0.927                 (29.4)  
2R0                                         14.00             (17.9)                  FIXED 
3dA (hr-1)                                0.041             (5.84)                   FIXED 
Inter-individual variability 
4ω2 [IC50] (%CV)                      141.8              (32)                        68.4                     
(156)       
 ω2 [γ] (%CV)                           NA                                                 97                       
(62.4)  
 ω2 [V0] (%CV)                          13                 (32.3)                    FIXED 
 
Residual Variability  
 
 5σ2 additive  (log10 copies/mL)        0.038           (15.1)                  0.037                (4.8) 
 
       
 6OFV                                              -727.81                                        -737.69 
 
Condition number                             5.8                                                10.9 
 
Table 2.2.: Comparison of parameter estimates from two population PK-PD/HIV 
viral dynamic models developed using phase IIa short-term monotherapy study for 
an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) drug; 
model 1 included only in vivo IC50 as a single PD parameter and model 2 included 
in vivo IC50 and in vivo γ in the portion of PD model. 1RSE: relative standard error, 
2R0: basic reproductive ratio, 3dA: death rate of actively infected cell, 4ω2 : variance 
of inter-individual variability, σ2: variance of residual variability, 6OFV: objective 
function value 
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Drugs Reference Parameters 
 
Estimates 
 
 
 
 
EFV 
 
Csajks C. et al. 
(2003) (Csajka, 
Marzolini et al. 2003) 
TV(CL/F) (L/h) 
TV(Vd) (L) 
TV(Ka) (h-1) 
F 
ω2 F 
9.4 
252 
0.30 
1 
0.298 
 
 
 
FTC 
 
 
Wang L.H. et al. 
(2004) (Wang, 
Begley et al. 2004) 
Hirt C.et al. (2009) 
(Hirt, Urien et al. 
2009) 
TV (Ka) (h) 
TV(Vc/F) (L) 
TV(CL/F) (L/h) 
TV(Q/F) (L/h) 
TV(Vp/F) (L) 
ω2 Ka 
ω2 CL/F 
0.97 
47 
21 
16 
50 
0.372 
0.029 
 
 
 
TDF 
 
 
 
 
 
Jullien V. et al. 
(2005) (Jullien, 
Treluyer et al. 2005) 
TV(CL/F) (L/h) 
TV(Vc/F) (L) 
TV(Q/F) (L/h) 
TV(Vp/F) (L) 
ω2 CL/F 
ω2 Vc/F 
Cov CL,V 
90.9 
534 
144 
1530 
0.0654 
0.370 
0.110 
Table 2.3.:  Model parameter estimates used for Monte Carlo simulation in order to 
evaluate the possible impact of γ on the long-term clinical outcome in combination 
regimen of Atripla; TV (parameter): typical value of the parameter, ω2 : variance of 
interindividual variability, Cov CL,V: covariance between η’s of CL/F and V/F 
52 
 
Figure 2.1.: (A,B) Plots of viral inhibition fraction over time for 5 hypothetical drugs 
with 5 different slope values at IQ of 5 (A) and IQ of 0.5 (B) using the same 
concentration profile. (C) Decay rate of viral inhibition fraction vs. slopes at different 
IQ values; IQ : Inhibitory quotient, the ratio between steady-state Ctrough and IC50 
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Figure 2.3.: Impact of γ for five hypothetical drugs with different γ values (= m) 
during 10 day monotherapy study. (A) Simulated drug concentrations, (B.1) the 
course of inhibition fraction (INH) and (B.2) log10 change in HIV-1 RNA  at IQ 
=0.5, (C.1) the course of inhibition fraction (INH) and (C.2) log10 change in HIV-
1 RNA  at IQ =5 ; IQ is inhibition quotient, the ratio between Ctrough and IC50 
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Figure 2.4.: Impact of γ for five hypothetical drugs with different γ values (= m) 
during 4 week monotherapy study with consideration of noncompliance (A) 
distribution of time intervals between successive doses by simulation of 
noncompliance, (B) simulated concentration-time curves under this 
noncompliance pattern; black bar is times for scheduled dosing, red bar is a 
sequence of simulated times at which one patient ingests a dose, (C.1) the 
course of inhibition fraction (INH) and (C.2) log10 change in HIV-1 RNA  at IQ 
=0.5, (D.1) the course of inhibition fraction (INH) and (D.2) log10 change in HIV-
1 RNA  at IQ =5  
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Figure 2.5.: Observed PK samples (A) and viral load profiles (B) obtained 
from phase IIa short-term monotherapy study in HIV-1 infected drug naïve 
patients (n=48) for an investigational NNRTI drug. 
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Figure 2.6.: Goodness of fit plots for the final population pharmacokinetic-
pharmacodynamic/HIV viral dynamic model including only IC50 as a single PD 
parameter for phase IIa short-term monotherapy study for an investigational  
NNRTI drug. 
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Figure 2.7.: Association between IC50 or γ and viral load decline on day 8 from 
baseline; (A) IC50 obtained from the final population PK-PD/HIV model including 
only IC50 in PD model, (B) & (C) IC50 and γ obtained from the final PK-PD/HIV 
model including both PD parameters in a phase IIa short-term monotherapy 
study for an investigational NNRTI drug 
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Figure 2.9.: Comparison between original data and simulated concentration-
time profiles for EFV (600mg), FTC (200mg) and TDF (300mg) 
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Figure 2.10.: Probability distribution of patients (%) with HIV-1 RNA <50 
copies/ ml at WEEK 48 (A) and comparison between observed (Gallant, 
DeJesus et al. 2006) and predicted patients (%) undetectable over time (B) 
from 100 trial simulation using the model with a dataset including1000 
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Figure 2.11.: Impact of γ on long-term clinical outcomes: % response over range 
of γ 
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Figure 2.12.: Log10 HIV-1 RNA-time profiles generated by Monte Carlo simulation 
(n=1000) using a population PK-PD/HIV viral dynamic model for Atripla treatment 
with  the value of γ  with either 1 or 2 for EFV under a scenario of development of 
drug resistance; (A) and (B) represent results from 1and 2 of γ , respectively; SI 
means simulation interval.  
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 Figure 2.13.: Simulation of the compliance pattern for combination therapy of 
EFV+FTC+TDF, using two-state markov model and normal timing error 
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Figure 2.14.: Log10 HIV-1 RNA-time profiles generated by Monte Carlo 
simulation (n=1000) using a population PK-PD/HIV viral dynamic model for 
Atripla treatment with different levels of γ for EFV under non-compliance of 
Atripla; each figure (A), (B) and (C) represent results from 1, 1.5 and 2 of γ , 
respectively. 
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Figure 2.15.: Log10 HIV-1 RNA-time profiles generated by Monte Carlo simulation 
(n=1000) using a population PK-PD/HIV viral dynamic model for Atripla treatment 
with different levels of γ for EFV under both scenario of non-compliance of Atripla 
and the development of drug resistance ; each figure (A), (B) and (C) represent 
results from 1, 1.5 and 2 of γ , respectively. 
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CHAPTER 3 
USE OF POPULATION PHARMACOKINETIC-PHARMACODYNAMIC/HEPATITIS 
C VIRUS VIRAL DYNAMIC MODEL TO EXAMINE THE IMPACT OF 
PHARMACODYNAMIC PARAMETERS OBTAINED FROM SHORT-TERM 
CLINICAL RESPONSE ON THERAPEUTIC OUTCOME 
 
 
What is already known about this subject:  
Previous models have been used to identify pegylated interferon (PEG-INF) α-2b 
pharmacodynamic (PD) and pharmacokinetic (PK) model parameters that were 
associated with improved clinical outcome in HIV/HCV-coinfected patients. These 
analyses found that EC50 was lower in sustained virological responders (SVR) 
compared to nonresponders (NR). 
What this study adds:  
This first population analysis using an integrated PK-PD/HCV viral dynamic model 
provides information on the high between-subject variability for IC50 and the death 
rate of infected cells (δ), but not on the Hill coefficient (γ) during PEG-INF-based 
therapy. The model showed that individual parameter estimates for IC50 and δ were 
significantly different between SVRs and NRs. The pharmacokinetic parameters and 
δ were not influenced by covariates, but IC50 in patients with HCV genotype-1 was 
higher than in those with HCV non-genotype 1.  
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SUMMARY 
AIM 
To examine whether pharmacodynamic parameters from the short-term clinical 
outcome studies are associated with Hepatitis C virus (HCV) therapeutic outcome,  
and whether patient-specific covariates or viral factors are associated with inter-
individual variability in therapeutic outcome, using an integrated population 
pharmacokinetic (PK)-pharmacodynamic (PD)-viral dynamic model. 
METHODS 
A sequential population PK-PD /HCV viral dynamic model was developed with 
NONMEM using published data which included pegylated-interferon (PEG-INF) α-2b 
concentrations and HCV RNA measurements during weeks 1 and 2, and patient 
baseline characteristics. A sigmoidal Emax model was used to link the 
pharmacokinetic and HCV viral dynamic model.  IC50 and the Hill coefficient (γ) were 
estimated in the pharmacodynamic component of model. The nonparametric Mann-
Whitney U test was used to assess the significance of difference in individual post-
hoc estimates (empirical Bayes estimates) of parameters between patients who 
attained sustained virologic response (SVR) and those who did not (NR).  
RESULTS 
The population PK-PD/HCV viral dynamic model adequately described the clinical 
data as assessed by visual inspection of diagnostic plots, precision of the parameter 
estimates, visual predictive checks and bootstrapping. The goodness-of-fit of the 
model increased significantly when γ was included (P < 0.001). However, inter-
individual variability on γ was not statistically significant. The model showed that 
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individual parameter estimates for IC50 and the death rate of infected cell (δ) were 
significantly different between SVRs and NRs. The pharmacokinetic parameters and 
δ were not influenced by covariates, but IC50 in patients with HCV genotype-1 was 
higher than that in those with HCV non-genotype 1 (0.55 µg/L vs. 0.16 µg/L).  
CONCLUSIONS 
The present study demonstrated no difference in γ between SVRs and NRs. 
Therefore, IC50 alone from early data is sufficient to describe drug effect for 
predicting clinical outcome of antiviral therapy.  
 
Key Words: integrated pharmacokinetic-pharmacodynamic/HCV viral dynamic 
model; IC50; Hill coefficient; NONMEM; interferon based therapy 
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INTRODUCTION 
The hepatitis C virus (HCV) is a leading cause of chronic liver disease and gives rise 
to a major public health problem globally. Approximately 170 million people 
worldwide are chronically infected with HCV, and more than 350,000 patients with 
HCV infection are estimated to die from HCV-related liver disease each year (World 
Health Organization). The primary goal of therapy for chronic HCV is to achieve a 
sustained virologic response (SVR), defined as an absence of detectable HCV RNA 
24 weeks after the completion of antiviral treatment. For decades, pegylated 
interferon (PEG-INF) administered in combination with ribavirin (RBV) for 48 weeks 
has been referred to as standard of care (SOC) for chronic hepatitis C (CHC). This 
combination therapy may result in SVR leading to HCV eradication, with a decrease 
in risk for cirrhosis, hepatic decompensation, and hepatocellular carcinoma 
(Nishiguchi, Kuroki et al. 1995; International Interferon-α Hepatocellular Carcinoma 
Study Group 1998).  
 
However, this therapeutic approach does not result in cure in all patients who 
undergo treatment. The likelihood of response varies greatly, depending on patient-
related factors such as race, cirrhosis, age, gender, and degree of liver fibrosis, as 
well as viral factors such as viral genotype and baseline viral load (Mihm, Herrmann 
et al. 2006). Viral factors correlated with SVR are genotype 2 and 3, as well as lower 
viral levels; host factors correlated with SVR are female sex, less fibrosis, lower 
body weight, and non-African-American race (Feld and Hoofnagle 2005). HCV 
genotype is especially considered as an important factor for SVR. In the United 
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States, genotype 1 is the most common (70-90 percent), followed by genotypes 2 
and 3. SVR rates in treatment-naïve patients receiving PEG-INF/RBV are 40-45% 
for viral genotype 1, and 70-80% for genotypes 2 and 3 (Ghany, Strader et al. 2009). 
Treatment with combination therapy carries risk of serious side effects that are 
dominated by fatigue, influenza-like symptoms, hematologic abnormalities, and 
neuropsychiatric symptoms (Fried 2002). Therefore, identification of clinically-
validated predictors of SVR using early clinical data would help optimize anti-HCV 
therapy and avoid administering toxic and costly therapy to patients with little chance 
of successful outcome.  
 
Previously, a mathematical model of HCV viral kinetics provided a means of 
estimating parameters of HCV viral kinetics, such as the rate of virion clearance and 
the rate of death of HCV-infected cell, and of effectiveness of therapy such as IC50, 
the median individual inhibitory concentration of PEG-INF for blocking viral 
production (Neumann, Lam et al. 1998). Furthermore, integration of HCV viral kinetic 
models into a PEG-INF pharmacokinetic (PK) model may be a powerful tool to better 
understand drug effect on HCV infection, and to support clinical study design 
combining knowledge of HCV infection and antiviral drug characteristics. A few 
studies have used an integrated PK-PD/viral dynamic model to evaluate the 
predictive ability of pharmacokinetic and pharmacodynamic parameters for 
sustained virologic responders. One study concluded that there was no difference in 
pharmacokinetic parameters, but IC50 was lower in SVRs compared with non-
responders (Talal, Ribeiro et al. 2006), while another study demonstrated that IC50 
77 
 
was significantly lower for Caucasians as compared to African-Americans and that 
pharmacokinetic parameters were similar among different groups of patients 
(Rozenberg, Haagmans et al. 2009) . 
 
Of particular interest in the current study was the development of a population 
pharmacokinetic (PK)-pharmacodynamic (PD)-viral dynamic model in order (1) to 
examine the predictive ability of pharmacodynamic parameters from early data on 
the virologic outcomes, (2) to investigate the effect of inter-patient variability on 
parameters of the integrated PK-PD/viral dynamic model, and (3) to evaluate 
whether patient-specific covariates or viral factors were associated with inter-patient 
variability in estimated parameters. In the pharmacodynamic model, the impact of 
the Hill coefficient (γ), which represents the sensitivity to changes in PEG-INF 
concentrations for blocking viral production on clinical outcome, was evaluated 
because the degree to which viral infection is inhibited at any given concentration 
depends not only on IC50, but also on γ. The importance of γ is not often considered 
during modeling, and it is commonly ignored (effectively fixed at a value of 1). 
However, drugs or patients which have similar IC50 values, but larger γ, can achieve 
much higher inhibition. In addition, patients or drugs with higher γ values may be 
associated with higher risk of non-response due to sharp declines in drug 
effectiveness as antiviral concentrations decline between doses.  
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METHODS 
Data Source 
Data were obtained from a previous publication (Talal, Ribeiro et al. 2006). In that 
study, 24 HCV/HIV-co-infected patients, who were PEG-INF α-2b/RBV-naïve, 
received PEG-INF α-2b 1.5 µg/kg once weekly and RBV 1000-1200 mg daily for up 
to 48 weeks. Individual patient PEG-INF α-2b concentrations, HCV RNA 
measurement during weeks 1 and 2, and patient baseline characteristics were 
available for the current model-building process.  
 
Population PK-PD/HCV model 
The population sequential PK-PD/HCV model (Figure 3.2) was developed using a 
non-linear mixed-effects modeling strategy as implemented in the NONMEM 
computer program   (version 7.1.2, ICON Development Solutions, Hanover, MD). 
Performance of the model was judged by both statistical and graphical analysis of 
goodness of fit and the minimal value of the objective function. An increase in 
goodness of fit was accompanied by a decrease in objective function, and this 
decrease was asymptotically distributed according to a χ2 distribution. A first analysis 
was performed to find the base model that best described the data. Once the 
appropriate base model was established, the influence of each covariate on 
pharmacokinetic parameters was tested. The following covariates were explored for 
further covariate model-building: race, baseline HCV RNA, inflammation, fibrosis, 
ALT, genotype, baseline HIV RNA, CD4+, and body weight. Due to minimal counts 
for some types of categorical variables such as race, inflammation, fibrosis and 
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genotype, these variables were expressed as dichotomous variables. Graphical 
methods and stepwise generalized additive modeling (GAM) analysis (Mandema, 
Verotta et al. 1992) with the Xpose program version 4.3.2 
(http://xpose.sourceforge.net) were used to explore the relationship between 
covariates and individual predicted pharmacokinetic parameters. A decrease in the 
objective function value of at least 3.84 (χ2 distribution with 1 degree of freedom for 
P < 0.05) relative to the base pharmacokinetic model was required for addition of a 
single fixed-effect parameter in the covariate model under the likelihood ratio test 
(LRT). Data processing and graphical analyses were conducted using R statistical 
software (version 2.12.2, http://www.r-project.org).  
 
Relative bioavailability (F1) between 1st dosing and 2nd dosing was tested in the 
model. Inter-individual variability (IIV) and inter-occasion variability (IOV) were 
evaluated. IOV between 1st dosing and 2nd dosing on pharmacokinetic parameters 
was implemented as follows:  
                        Vd = θ ∙exp (η1 + η2∙WEEK1 + η3∙WEEK2)                            
where θ is the typical value of the volume of distribution, variables WEEK1 and 
WEEK2 were dichotomous covariate set equal to ‘1’ to denote the occasion and ‘0’ 
otherwise, η1 denotes the random effect on Vd in the absence of IOV, and η2= η3. η1 
+ η2 represents the random effect during 1st dosing on week 1 and η1 + η3 
represents the random effect during 2nd dosing on week 2. Proportional, additive and 
combined proportional and additive error models were evaluated to describe residual 
variability. After developing and validating the final pharmacokinetic model, the 
(Eqn. 3.1) 
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estimated individual pharmacokinetic parameters calculated by empirical Bayes 
estimation were included in the dataset for further development of the PD/HCV 
model. 
 
The sigmoidal Emax model was used to characterize the drug effectiveness () as a 
function of time as follows:  
                                                   ε = 
    
 
    
 
     
                                 
where IC50 is the PEG-INF concentration, C(t), at which the drug’s effectiveness (ε) in 
blocking viral production is half its maximum, and γ determines how steeply the drug 
effectiveness rises and decreases with concentration fluctuation.  
 
The effectiveness (ε) was incorporated into HCV viral dynamic model (Eqn. 3.3 -3.5) 
to describe HCV viral load decline in the presence of antiviral drug. Population 
predictions from the NONMEM analysis subroutines and ADVAN13 with TOL=9 
were employed for this integrated PK-PD/viral dynamic model. According to previous 
work (Neumann, Lam et al. 1998), the antiviral effect of IFN α is mainly in blocking 
viral production from infected cells. Thus, the following modified equations from the 
original model (Neumann, Lam et al. 1998)  were used:  
                                    
     
  
                                               
                                   
     
  
                                                           
                                   
     
  
                                                    
(Eqn. 3.2) 
(Eqn. 3.3)
(Eqn. 3.4) 
(Eqn. 3.5) 
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where T(t) represents target uninfected hepatocytes, I(t) represents productively-
infected hepatocytes, and V(t) free viruses. Target uninfected cells are produced at 
rate S and die with death rate dT. The infected hepatocytes become infected with 
infection rate β and cleared with rate δ. Hepatitis C virions are produced with rate ,p 
and free virus are cleared with rate c. The rate of viral replication within a patient at a 
given time can be re-parameterized as the basic reproductive ratio (R0), which is 
defined as the average number of newly-infected cells that arise from any one 
infected cell in the beginning of the infection when almost all cells are uninfected 
(Bonhoeffer, May et al. 1997). 
                                           
     
      
                                          
Before treatment, the intrinsic clearance of virions and viral production are assumed 
to be in equilibrium, with an additional equilibrium between infection rate and loss 
rate of infected cells, expressed as dT/dt=dI/dt=dV/dt=0 in differential equations. 
From this steady-state condition, initial conditions of virus and host cell were derived 
from estimated parameters as follow: 
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(Eqn.3.6) 
(Eqn. 3.7) 
(Eqn. 3.8) 
(Eqn. 3.9) 
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Assumptions in the model 
Due to issues of mathematical identifiability, it is inevitable that some model 
parameters must be fixed to predefined values which are often reported in the 
literature. Therefore, the following parameters were set to fixed values: S=61.7 x 103 
(hepatocytes/ml/day, target cell production rate) (Colombatto, Civitano et al. 2003), 
dT=0.003 (per day, target cell death rate) and c=6.2 (per day, virion elimination rate) 
(Snoeck, Chanu et al. 2010). It was possible to derive p from V0 x c /I0 using 
baseline HCV RNA, virion elimination rate, and the amount of infected cells at initial 
condition.  
 
Evaluation and qualification of the model 
To perform a visual predictive check, the parameter estimates defined by the final 
pharmacokinetic model and by the final integrated PK-PD/viral dynamic model were 
fixed and used to simulate 1000 datasets and 200 datasets, respectively, with the 
SIMULATION SUBPROBLEMS option of NONMEM. From the simulated data, 90% 
prediction intervals (PIs) were calculated and superimposed on observed data from 
the original dataset to evaluate whether at least 90% of data points were within the 
PI, which is indicative of an adequate model. Furthermore, model stability was 
evaluated with nonparametric bootstrapping (Efron and Tibshirani 1993) using the 
software Perl-speaks-NONMEM (PsN) (Lindbom, Ribbing et al. 2004) version 3.2.12 
(http://psn.sourceforge.net). The original population parameters for the final 
pharmacokinetic model were compared with the median values and 90% confidence 
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intervals for the parameter estimates obtained from 200 bootstrap replicates of the 
original dataset.  
 
Statistical analysis 
The nonparametric Mann-Whitney U test was used to assess the significance of 
differences in individual post-hoc estimates of pharmacodynamic parameters 
between SVR and NR at 72 weeks. Three patients who did not complete the study 
due to treatment-related side effects or noncompliance were excluded from this 
analysis. A P value <0.05 was considered statistically significant. 
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RESULTS  
The availability of published individual PEG-INF α-2b concentrations, HCV RNA 
measurements (Figure 3.1), and patient baseline characteristics (Table 3.1) allowed 
PEG-INF α-2b pharmacokinetics to be related to pharmacodynamic/viral kinetic 
profiles in order to understand the relationship between short-term drug effect and 
eventual clinical outcome, as well as to investigate the possible patient baseline 
characteristics that might be associated with the inter-individual variability for each of 
the parameters estimated in the model.  
 
Population pharmacokinetic analysis 
The population pharmacokinetic model for PEG-INF α-2b was optimal with a single 
compartment and first-order absorption and elimination. NONMEM analysis 
subroutines ADVAN2, TRANS2, using FOCE with η-ε interaction for the method of 
parameter estimation, was employed. In the initial analyses, a two-compartment 
model structure failed to improve the objective function compared to a one-
compartment system, and so a one-compartment model was chosen as the best 
structural model. The OFV for the one-compartment model decreased significantly in 
response to the inclusion of inter-individual variability on Ka, CL/F and Vd/F (P < 
0.001). The OFV of the pharmacokinetic model decreased significantly with the 
inclusion of inter-occasion variability between the 1st week of dosing and the 2nd 
week of dosing only on the apparent volume of distribution (P < 0.001). Screening of 
the effects of covariates on pharmacokinetic parameters during the GAM analysis 
and stepwise analysis in NONMEM showed that none of the covariates significantly 
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improved the goodness of fit. The final pharmacokinetic parameters are detailed in 
Table 3.2. The goodness-of fit assessment revealed that the concentration profiles 
were well-described by the model without systemic bias (Figure 3.3). Individual 
predictions by the final model correspond to individual concentration observations 
(Figure 3.4). The simulated concentrations for 1000 patients using the final model 
are depicted in Figure 3.5. The majority of the observed PEG-INF α-2b 
concentrations were within the range of the lower (2.5%) and upper (97.5%) 
percentiles of the simulated concentrations. 
 
Population PK-PD /HCV viral dynamic model analysis  
In the sequential population PK-PD/HCV viral dynamic model, the parameter 
estimates from the final pharmacokinetic model were fixed and used to simulate 
individual drug concentrations at times of pharmacodynamic measurements.  The 
parameters for the pharmacodynamic model then were estimated, and are shown in 
Table 3.3. The OFV for the model did not decrease significantly in response to the 
inclusion of inter-individual variability on R0 and baseline HCV viral load (P > 0.05). 
The OFV for the model increased significantly in the presence of the population 
mean value of γ  in the pharmacodynamic portion of the model (P < 0.001), which 
was estimated with a value of approximately 3. However, the OFV did not reduce 
significantly with the inclusion of inter-individual variability on γ (P > 0.05); 
furthermore, the range of estimated individual γ values when inter-individual 
variability was included in the model was between 2.83 and 2.99. The infected 
hepatocyte death rate (δ) was found to not be influenced by race, baseline HCV, or 
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HCV genotype. However, the final model predicted that IC50 of PEG-INF α-2b was 
influenced by HCV genotype in this study population.  IC50 in patients with HCV 
genotype 1 was found to be higher than that in those with HCV non-genotype 1, 
which explains higher inhibition potency of PEG-INF α-2b in patient with HCV non-
genotype 1. Goodness-of-fit plots (Figure 3.6) and individual fit (Figure 3.7) of the 
HCV RNA measurement revealed that the model provided a good description of the 
observed data. The predicted HCV viral loads for 100 simulations by the final model 
are shown in Figure 3.8. The majority of the observed data were within the range of 
the lower (2.5%) and upper (97.5%) percentiles of the simulated viral loads. 
 
Relationship between parameter estimates of pharmacodynamic/HCV viral 
dynamic model in weeks 1 and 2 and long-term clinical outcomes  
The model revealed that individual parameter estimates for IC50 and the infected cell 
death rate (δ) were significantly different between patients who attained SVR and 
patients who did not (P < 0.05)  (Figure 3.9). Inhibitory quotient (IQ), the ratio 
between Ctrough and IC50, as well as average inhibition fraction (INH) for the 1
st week 
of therapy in patients who eventually attained SVR, were higher than those for 
patients who did not evidence SVR.   
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DISCUSSION  
In the present study, the relationship between pharmacodynamic parameters from 
early therapy and clinical outcome, which included SVR, was examined. The 
integrated population PK-PD/HCV model developed in this effort yielded an 
adequate description of the time course of PEG-INF α-2b concentrations and HCV 
RNA. The nonlinear mixed effect modeling approach facilitated identifying 
parameters of the PK-PD/HCV model, which showed high inter-patient variability, 
and further investigated patient-specific or viral-specific covariates that could 
possibly contribute to that high inter-patient variability. In addition, the model 
developed was used to investigate the relationship between the empirical Bayes 
estimate (EBE) for individual pharmacodynamic parameters and clinical outcome. 
 
Regarding the relationship between pharmacodynamic parameters and clinical 
outcome, the mean IC50 in non-responders (NR) was higher than that in SVRs. A 
previous study developed a model for the same dataset with nonlinear least-squares 
regression analysis utilized the median values of IC50 between SVRs and NRs.  
(Talal, Ribeiro et al. 2006). However, in this previous study the accuracy of 
estimates of pharmacodynamic parameters was in question due to inappropriate 
values for CIs of these estimates. In contrast, the population approach used in the 
present study recovered estimates of the pharmacodynamic parameters with high 
accuracy (RSE < 50%) and reasonable values for 90% CI from bootstrap analysis. 
Including γ as a parameter in the model improved the goodness-of-fit, but there was 
no difference in values of γ between patients who attained SVR and those who did 
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not in the study population. Therefore, IC50 alone from early data (collected in short-
term studies) might be sufficient to describe drug effect for the purpose of predicting 
clinical outcome. Furthermore, this study demonstrated that IC50 in subjects with 
HCV genotype 1 was significantly higher than that in subjects with HCV non-
genotype 1, corresponding to clinical observation that patients with HCV genotype 1 
evidence a lower response rate (Manns, McHutchison et al. 2001; Fried, Shiffman et 
al. 2002) . A recent study in a large number of patients also showed similar results: 
the ED50, i.e., the estimated weekly dose of PEG-INF α-2b  that resulted in a 50% 
inhibition of the virion production, for patients with the HCV genotype 1 was 
significantly higher than those of patients with HCV non-genotype 1 (Snoeck, Chanu 
et al. 2010).  
 
The typical response to IFN therapy evidences a biphasic decline in HCV RNA 
levels (Neumann, Lam et al. 1998). The first phase of decline in HCV viral loads is a 
rapid, dose-dependent phenomenon that persists for 1-2 days after treatment 
initiation (Neumann, Lam et al. 1998; Guo, Bichko et al. 2001). The slope of the first 
phase of decline is determined by the viral clearance and the drug efficacy, and is 
not correlated with baseline viral load (Neumann, Lam et al. 1998). The second 
phase of viral decay is slower and not dose-dependent. This phase reflects the 
death rate of the infected cell as well as the efficacy of the drug (Neumann, Lam et 
al. 1998). In particular, high inter-patient variability has been observed in the slope of 
the second phase, and this variability has been suggested to be due to differences in 
anti-HCV cytotoxic T lymphocyte (CTL)-mediated immune response (Rong and 
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Perelson). In the present study, high inter-patient variability in the death rate of 
infected cells (δ) was estimated, and that variability was even higher than inter-
patient variability associated with IC50. The results of the current study further 
suggested that none of the examined covariates could explain the high inter-patient 
variability associated with δ. In contrast, a previous study by Snoeck E. et al. 
(Snoeck, Chanu et al. 2010) reported a slightly higher δ in patients with HCV non-
genotype 1 (0.192 day-1 vs. 0.139 day-1 in δHCV non-1 and δHCV -1, respectively). The 
current study showed the death rate of infected cell was higher in SVRs compared to 
that in NRs.  
 
On examination of patient-specific covariates that might be associated with high 
inter-individual variability for parameters of the PK-PD/HCV model, none of the 
covariates was significantly associated with inter-individual variability in 
pharmacokinetic parameters. It was reported that baseline CD4+ T-cell counts ≥ 450 
cells/mm3 were significantly associated with SVR in co-infected genotype-1 patients 
(Avidan, Goldstein et al. 2009). Therefore, the influence of baseline CD4+ T cell 
counts on the IC50 and the infected cell death rate also was examined in the current 
study in order to investigate whether patients with baseline CD4+ T-cell counts ≥ 450 
cells/mm3 may have low IC50 or high infected cell death rate. This covariate was 
statistically insignificant and did not improve the model fit.  
 
It also has been reported that African-Americans had slower hepatitis C virus viral 
kinetics as compared to Caucasians (Layden-Almer, Ribeiro et al. 2003). In the 
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present study, race was not significantly associated with inter-individual variability in 
IC50 and infected cell death rate during model development. The relatively small 
sample size in this study may limit the conclusions that can be drawn with respect to 
this point, however. A low baseline viral load (2 x 106 c/ml or less) was significantly 
associated with improved rates of SVR (Mihm, Herrmann et al. 2006). However, the 
population in this study did not have differences in baseline HCV and there was no 
correlation between baseline HCV and any of parameter estimates of the developed 
PK-PD/HCV model.  
 
While developing the population PK-PD/HCV viral dynamic model, only PEG-INF 
concentration-time profiles were used due to unavailability of RBV concentration-
time profiles. A previous study showed that co-administration of RBV did not affect 
the absorption rate and half-life of PEG-INF (Glue, Rouzier-Panis et al. 2000). 
Although RBV does not influence to pharmacokinetics of PEG-INF, co-administration 
of RBV with interferon significantly improves long-term response rates in HCV 
infection (McHutchison, Gordon et al. 1998; Reichard, Norkrans et al. 1998). 
Therefore, it is possible the IC50 of PEG-INF in the PK-PD/HCV viral dynamic model 
would be under-estimated when describing the drug effect of PEG-INF if RBV and 
PEG-INF have a similar pharmacodynamic mechanism in causing decline HCV viral 
loads and if the effect due to RBV is ignored.  
 
The RBV pharmacodynamic mechanism for the increase in the response rate to INF 
is still unknown, but multiple mechanisms have been proposed (Feld and Hoofnagle 
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2005). RBV monotherapy did not change viral levels and did not clear HCV even 
with prolonged treatment (Di Bisceglie, Conjeevaram et al. 1995; Hoofnagle, Lau et 
al. 1996). One proposed mechanism is that RBV, a purine analogue, is incorporated 
into the RNA of replicating virions, thereby increasing the mutation frequency and 
reducing the specific infectivity of new virions (Crotty, Cameron et al. 2001). In the 
present study, the association between pharmacodynamic parameters that were 
estimated only from early 2-week data of PEG-INF α-2b and clinical outcome was 
examined. In the future, it will be necessary to evaluate whether the PK-PD/HCV 
viral dynamic model based on early clinical data from only PEG-INF administration 
(i.e., the model developed in the current study) is able to predict HCV viral loads for 
long-term treatment. Furthermore, it is important to investigate whether using 
pharmacokinetic concentration-time profiles for both PEG-INF and RBV as part of a 
PK-PD/HCV viral dynamic model would influence the estimates of 
pharmacodynamic parameters for PEG-INF.  
 
Currently, there are endeavors in the development of direct-acting antiviral agents 
(DAAs) that interfere with specific steps in the HCV replication cycle for the 
treatment of chronic HCV infection (De Francesco and Migliaccio 2005; Cheng, 
Gupta et al. 2011; Soriano, Vispo et al. 2011). However, newer agents are still likely 
to be used in combination with PEG-interferon and RBV (Nelson ; De Francesco and 
Migliaccio 2005). In 2011, two direct-acting HCV drugs, Boceprevir (Merck) and 
Telaprevir (Vertex)  were approved by the FDA for use in combination with PEG-INF 
α and RBV for the treatment of genotype-1 CHC. Therefore, it would be valuable to 
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better understand pharmacodynamic action, and to develop appropriate PK-PD/HCV 
models for the combination therapy with PEG-INF, in order to support the 
development of the new agent and regimens.  
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Categorical Covariates               Category                                     N (%) 
RACE                                    African American                              12 (50%) 
                                              Caucasian                                         12 (50%) 
 
Genotype                               HCV genotype-1                                21 (87.5%) 
                                             HCV non-genotype-1                          3 (12.5%) 
 
Inflammation*                                 ≤ 2                                            14 (58.3%) 
                                                      > 2                                            10 (41.7%) 
 
Fibrosis*                                          ≤ 2                                           11 (45.8%) 
                                                        > 2                                          13 (54.2%) 
 
Continuous Covariates (unit)                      Mean                             SD 
Baseline HCV ( log10 IU/mL)                           6.10                             0.75 
  Baseline HIV   (copies/mL)                            14230                           42090 
  CD4  (cells/µL)                                               476.5                            217.7 
     Weight (kg)                                                    82.86                            9.8 
 
  
Table 3.1.: Summary of patient characteristics [Talal, A. H.2006]; *inflammation 
and fibrosis were assessed using the Scheuer system 
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Parameter 
Estimation  Bootstrap 
Final estimation  1RSE(%)  Median            95% CI 
FIXED EFFECT 
Ka (day
-1)                         0.36            (13.3)                      0.37            (0.28 – 0.47) 
CL/F (L/day)                    39.8           (6.21)                       39.6            (34.9 – 44.2)  
Vd/F (L)                           25.9            (19.0)                       26.7            (17.5 – 38.7) 
Inter-individual variability 
ω2 [CL] (%CV)                 28.2                                            26.7            (17.4 – 35.9)       
ω2 [Vd] (%CV)                   77.6                                            76.5            (41.7 – 108)  
ω2 [Ka] (%CV)                   45.6                                            44.6            (14.7 – 69.9) 
Inter-occasion variability 
2IOV [Vd]  (%CV)                 43.7                                           43.5            (20.5 – 62.7) 
Residual Variability  
σ2 proportional  (%)                       28              (13.0)                       29.3           (25.2 – 32.7) 
  
Table 3.2.: Final parameters of population pharmacokinetic model; 
1relative standard error, 2inter-occasion variability 
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Parameter  
Estimation 
 
Bootstrap 
Final estimation   RSE(%) 
 
Median          95% CI*   
FIXED EFFECT 
IC
50
 (µg/L) 
HCV-1
                     0.55           (17.0)             0.55       (0.34 – 1.00) 
IC
50
 (µg/L) 
HCVnon-1
                 0.16           (44.2)             0.17       (-0.51 – 0.97) 
γ                                             2.86          (13.2)             2.91        (1.83 – 4.92) 
S (hepatocytes/ml/day)    61.7*10
3
    FIXED                       
d (per day)                             0.003         FIXED 
c (per day)                             6.2             FIXED 
δ  (per day)                            0.32           (39.4)            0.35       (0.14 – 0.81) 
R
0
                                          12.4            (36.4)           13.4        (4.02 – 36.7)                    
IIV (CV%) 
ω
2  
(δ)
                                                     
136                                  132         (59.9 – 191) 
ω
2  
(IC
50
)
                         
               68.6                                 70.7        (38.4 – 127) 
Residual Variability  
σ
2
 
add
 (IU/ml)                          0.085         (9.18)            0.082       (0.06 – 0.10) 
 
 
 
 
 
 
 
 
Table 3.3.: Final parameters of population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model;1production rate of uninfected 
hepatocyte, 2death rate of uninfected hepatocyte, 3viron clearance rate,                     
4death rate of infected hepatocyte, 5basic reproductive ratio; Some model 
parameters was fixed to predefined values which are usually reported in the 
literature [Bonhoeffer, S., R, 1997] due to issues of mathematical identifiability.  
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Figure 3.2.: Scheme depicting the pharmacokinetics-pharmacodynamic/HCV 
viral dynamic model of pegylated-interferon based treatment.  
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Figure 3.3.: Goodness-of-fit plots of population pharmacokinetic model 
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Figure 3.4.: Individual plot of population pharmacokinetic model. 
 
100 
 
Figure 3.5.: Visual predictive check plot of population pharmacokinetic model  
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Figure 3.6.: Goodness-of-fit plots for sequential population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model 
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Figure 3.7.: Individual plot of sequential population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model. 
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Figure 3.8.: Visual predictive check plot of sequential population 
pharmacokinetic-pharmacodynamic/HCV viral dynamic model. 
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Figure 3.9.: Box plots for the relationship between the empirical Bayes estimates 
(EBE) for parameters obtained from the final PK-PD/HCV viral dynamic model in 
early (2-weeks) and long-term clinical outcome (SVR). NR indicates non-
responder.  
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CHAPTER 4 
PREDICTION OF LONG-TERM HCV TREATMENT OUTCOME USING A 
POPULATION PHARMACOKINETIC-PHARMACODYNAMIC-HCV VIRAL 
DYNAMIC MODEL DEVELOPED FROM SHORT-TERM OUTCOMES 
 
SUMMARY 
 PURPOSE: In this study, long-term clinical outcomes were predicted based on a 
population pharmacokinetic-pharmacodynamic/viral dynamic model following short-
term therapy with pegylated interferon (PEG-INF). 
 METHODS: Data were obtained from a previous publication (Talal, A.H. et al. 
2006), which included 24 HCV/HIV-co-infected patients who received PEG-IFN α-2b 
1.5 µg/kg once weekly and ribavirin (RBV) 1000-1200 mg daily for up to 48 weeks. 
Individual concentration-time and HCV RNA measurement-time profiles were used 
to develop a sequential population PK-PD/HCV viral dynamic model using 
NONMEM. The adequacy and stability of the final model was evaluated by visual 
predictive check and bootstrap, respectively. A total of 1000 simulation trials were 
performed, and the sustained virologic response (SVR) of the original study was 
compared with the model-predicted SVRs. Simulation of RBV effectiveness (Dixit, 
N.M et al. 2004) also was integrated into the model as RBV concentration data were 
not available. In addition, a virus-eradication boundary (Snoeck, E. et al. 2010) was 
implemented in the model to describe SVR.  
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 RESULTS: The model adequately described the observed data at Week 2. 
Simulation of long-term therapy using the model parameters recovered from short-
term treatment data showed that the observed SVR outcome falls within the range of 
model predictions. Inclusion of RBV drug effect adequately described the viral load 
decline for patients with HCV genotype-1.  
 CONCLUSIONS: Long-term HCV treatment outcomes can be predicted 
reasonably using a population pharmacokinetic-pharmacodynamic/viral dynamic 
model developed from short-term two week treatment with PEG-INF.  
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INTRODUCTION  
    Chronic hepatitis C virus (HCV) infection has a world-wide prevalence of 
approximately 3% and is a leading cause of chronic liver disease (World Health 
Organization). The goal of therapy for chronic hepatitis C (CHC) infection is to 
eradicate the virus and prevent progression of liver disease associated with HCV 
infection. Successful treatment of CHC infection is indicated by undetectable virus in 
serum 24 weeks after stopping antiviral therapy, which is termed a sustained 
virologic response (SVR). SVR is associated with an extremely low risk of persistent 
HCV or recurrence during longer follow-up (Giannini, Basso et al. 2010), and has 
been used as the primary endpoint in all clinical trials to evaluate drug efficacy, as 
well as by clinicians in treating patients.  
The combination of pegylated interferon (PEG-INF)-α with ribavirin (RBV) has 
been used as the standard of care for CHC patients for decades. PEG-INF and RBV 
also will continue to remain a mainstay of the future HCV treatment because the use 
direct-acting HCV drugs, such as protease or polymerase inhibitors, in combination 
with PEG-INF and RBV increases antiviral activity while also suppressing the 
selection of resistant variants (Nelson ; De Francesco and Migliaccio 2005). 
Approximately 50% of patients with HCV are infected with the HCV genotype 1, 
which represent about 70% of CHC patients in the United States (Hill 1910), 
achieved an SVR (Hill 1910; Nishimoto and Ellner 1983) following therapy with PEG-
INF and RBV.   
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    Mathematical models have provided important quantitative insight into 
interpreting results from clinical studies in chronic viral infections such as HIV, HCV 
and HBV, as well as investigations of antiviral treatment effects (Perelson 2002). 
Early studies modeling HCV data obtained from individual patients were able to 
elucidate those in vivo viral kinetic parameters that are not directly measurable, e.g., 
hepatocyte death, and showed mathematically how INF in combination with RBV 
affects HCV treatment (Neumann, Lam et al. 1998; Giannini, Bodini et al. 2010). 
These original models were based on the assumption of constant drug 
effectiveness, although in reality drug effectiveness is altered in accordance with 
fluctuating drug concentrations between doses. Therefore, an incorporated 
pharmacokinetic (PK)/pharmacodynamic (PD)/HCV viral dynamic model was 
developed to describe HCV kinetics in the presence of time-varying INF 
effectiveness (Dimova and Talal ; Powers, Dixit et al. 2003; Perelson, Herrmann et 
al. 2005; Talal, Ribeiro et al. 2006; Shudo, Ribeiro et al. 2009). Although this model 
was able to describe the initial rapid viral decline followed by a second, slower 
decline until HCV RNA became undetectable after short-term combination treatment 
of PEG-INF and RBV, all phenomena associated with the observed HCV RNA 
profiles (such as null response, a partial response, breakthrough during therapy and 
a relapse after therapy, and, importantly, an SVR) were still unexplainable by this 
model (Giraud, Rey et al. 2006).  
    Recently, Snoeck E. et al. made significant progress in HCV viral dynamic 
modeling by incorporating a viral eradication/cure boundary that appropriately 
characterizes SVR (Snoeck, Wade et al. 2006). This model is based on physiologic 
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reality: virion production should terminate when all infected cells are cleared in 
response to drug therapy. In this model, the HCV virion production rate was 
therefore set to zero at the time at which the drug effect drives the system to a status 
of less than one infected hepatocyte. 
    The incorporation of statistical techniques such as a nonlinear mixed effects 
model in the classic PK-PD/viral dynamic model for estimation of fixed effects, inter-
individual and residual variability has been implemented in the NONMEN software 
(Jullien, Treluyer et al. 2005) and in the MONOLIX software.  Nonlinear mixed effect 
models (Giannini, Savarino et al. 2011) can quantify, explain, and predict how 
variability in drug concentration affects variability in drug effect, and what patient 
factors may be the source of the variability in pharmacokinetics and 
pharmacodynamics  
    Over the past 15 years, the advance in mathematical models of HCV viral 
dynamics and statistical methods has made a significant contribution to the 
understanding of viral kinetics and how newer forms of treatment may affect viral 
load and how viral kinetics differ between viral genotypes. In addition, these 
approaches have addressed the ability to predict treatment outcomes as early as 
possible in therapy, and have provided insight into why some groups of patients 
respond to therapy while others do not.  
    It is unknown whether a PK-PD/viral dynamic model developed using available 
data obtained from short-term therapy is capable of predicting long-term clinical 
outcome. Treatment with PEG-INF plus RBV is associated with adverse effects such 
as neuropsychiatric events, flu-like symptoms, and neutropenia (Ghany, Strader et 
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al. 2009).  Early detection of non-SVR is of major importance to avoid unnecessary 
treatment-related morbidity. A model that accurately predicts long-term clinical 
outcome also is critical in comparing efficacy among varying therapeutic regimens in 
drug development.  
In this present study, the probability of model-predicted SVR was compared by 
Monte Carlo simulation with the observed SVR in order to evaluate whether the 
population pharmacokinetic-pharmacodynamic/viral dynamic model developed from 
early clinical data with PEG-INF-based treatment is able to reasonably predict the 
long-term clinical outcome. 
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METHODS 
    Individual PEG-IFN α-2b concentrations, 2-week measurement of HCV RNA, 
and patient baseline characteristics were obtained from a previous publication (Talal, 
Ribeiro et al. 2006). 24 HCV/HIV-co-infected, PEG-IFN α-2b/RBV-naïve patients 
received PEG-IFN α-2b 1.5 µg/kg once weekly and RBV 1000-1200 mg daily for up 
to 48 weeks. The majority of the subjects were HCV genotype-1 (87.5 %) with only 3 
non-genotype 1 subjects (12.5 %).  
Exploratory deterministic long-term clinical outcome simulation  
    Prior to performing Monte Carlo simulations to assess the predictability of long-
term clinical outcome using the PK-PD/HCV viral dynamic model developed in 
Chapter 3, the model was first implemented in Berkeley Madonna (Version 8.3.18) 
(Koblin, Husnik et al. 2006) in a deterministic setting. In this stage, the impact of 
RBV drug effect on viral load decline also was evaluated since RBV concentration 
data were not available during modeling-building in the studies reported in Chapter 
3. The basic model was modified to include the RBV drug effect using Eqn. 4.2 to 
mimic the slow accumulation of RBV in plasma.  
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where ε(t) is the time-varying effectiveness of PEG-INF, IC50 is the estimated PEG-
INF concentration that results in a 50% inhibition of the virion production, γ is the 
(Eqn. 4.1) 
(Eqn. 4.2) 
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estimated Hill coefficient that determines the shape of the relationship between 
concentration and drug effect, ρ(t) is the time-varying effectiveness of RBV, ρmax is 
the maximum effect of RBV and we assume that RBV renders the maximum 50% of 
virus population non-infectious by RBV drug effect (Giannini, Bodini et al. 2010), ta is 
the accumulation timescale of RBV effectiveness that was fixed at 5.6 days thereby 
allowing ρ to slowly increase from 0 at time=0 to ρmax around time=28 day (Giannini, 
Bodini et al. 2010).  
    Pharmacodynamic effectiveness of PEG-INF and RBV was incorporated into 
the HCV viral dynamic model (Eqn. 4.3 - Eqn. 4.6.). 
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where infectious HCV virions (VI) infect uninfected target hepatocytes (T) to create 
productively-infected hepatocytes (I) at rate β∙T∙VI. Uninfected hepatocytes are 
produced at rate S and die at rate dT. Infected hepatocytes die at rate δ. In the 
absence of therapy, an infected cell generates new virions at rate p and generated 
virions die at rate c. During therapy, PEG-INF inhibits p by a factor (1-ε) (Neumann, 
Lam et al. 1998) and RBV renders a fraction ρ non-infectious, generating VNI 
(Eqn. 4.3) 
(Eqn. 4.4) 
(Eqn. 4.5) 
(Eqn. 4.6) 
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(Giannini, Bodini et al. 2010). The measured viral load (V) is the sum of infectious 
and non-infectious virions: V=VI+VNI. The typical values of each of the parameters 
estimated using the model in chapter 3 were used for this deterministic simulation, in 
which Ka=0.36 day
-1, CL=39.8 L/day, Vd=25.9 L, IC50=0.16 µg/L for HCV non-
genotype 1, IC50=0.55 µg/L for HCV genotype 1, δ=0.32 day
-1 and R0=12. 
    The impact of incorporating a cure/virus-eradication boundary (Snoeck, Chanu 
et al.) into the model in order to characterize the SVR (Eqn. 4.7 – Eqn. 4.8) was 
examined further: 
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where virion production (p) was set to zero at the time point when the treatment 
drives the system to a status of less than one infected hepatocyte (I) (Eqn. 4.8).  
When there are more than 1 hepatocyte, p is derived using baseline HCV RNA, 
virion elimination rate and the amount of infected cells at initial condition (Eqn. 4.7).  
Finally, the model that was able to explain SVR for long-term simulation was used to 
explore the slope (γ) coefficient on viral load decline 
  
Monte Carlo Simulation for stochastic long-term clinical outcomes 
    The final model evaluated using Berkeley Madonna software was then 
implemented in NONMEM in a Monte Carlo fashion, which included random noise 
terms for both assay error and inter-individual variability. For the Monte Carlo 
simulation study, the population PK-PD/HCV viral dynamic model (Figure 4.3.) was 
When I ≥1               (Eqn. 4.7) 
When I < 1             (Eqn. 4.8) 
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first fit to HCV viral load data during a 2-week clinical study (Talal, Ribeiro et al. 
2006) using nonlinear mixed effects modeling methodology as implemented in the 
NONMEM software (version 7.1.2, ICON Development Solutions, Hanover, MD). 
Parameter estimation was performed using the subroutine ADVAN 13 (Johnson, 
Chesney et al. 2006) and first-order conditional estimation (FOCE) with 
INTERACTION. During this model-fitting, patients with HCV non-genotype 1 were 
excluded due to their small number (n=3). Parameter estimates from the two models 
(one including a pharmacodynamic model of RBV and the other not including the 
pharmacodynamic model of RBV) were compared in order to investigate how the 
inclusion of a pharmacodynamic model for RBV would impact other parameter 
estimates. The final population PK-PD/HCV viral dynamic model included the 
pharmacodynamic model of RBV to describe RBV drug effect on viral load decline. 
Performance of the model was judged by both statistical and graphical analysis of 
goodness of fit as well as minimal value of the objective function. The adequacy of 
the final model was evaluated by visual predictive check. After model-building and 
validation from the first 2 weeks of data from the clinical study, 1000 trials were 
stochastically simulated using Monte Carlo simulation with 2 evels of random effects 
estimated from the final model: inter-individual variability (Eqn.4.9-4.12 for PK and 
Eqn. 4.13-14 for pharmacodynamic) and residual variability (Eqn. 4.12 for PK and 
Eqn. 4.15 for clinical observation, in this case, viral load (copies/mL)). 
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where i, j, and k are the number of individuals (i=1,2,3…..21), time points 
(j=0,……72 weeks), and simulation trials (k=1,2,3…. 1000), respectively, CLi, Kai, 
Vdi , IC50i and δi are simulated clearance, the rate constant for absorption, the 
apparent volume of distribution, the concentration that inhibit 50% maximum drug 
effect, and the rate of infected cell death of PD/HCV viral dynamic model 
parameters, respectively, for an individual i, θµ is the mean value of parameters 
obtained from the final model, ηi is the deviation of the i
th individual from mean 
values of those parameters (θµ). The η values are assumed to be independent, have 
mean zero, and constant variance model parameters ω2 (obtained from the final 
model), ε is residual and is assumed to be independent, have zero mean, and 
constant variance model parameters σ2 (obtained from the final model), Ci,j,k and Vi,j,k 
(Eqn. 4.9) 
(Eqn. 4.10) 
(Eqn. 4.11) 
(Eqn. 4.12) 
(Eqn. 4.13) 
(Eqn. 4.14) 
(Eqn. 4.15) 
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are simulated concentration and HCV viral load measurement respectively at time j 
for an individual i at a simulation trial k.   
    Implementation of a cure/virus-eradication boundary (Eqn. 4.7 – Eqn. 4.8) also 
was applied to this Monte Carlo simulation to characterize the SVR. The probability 
of SVRs obtained from 1000 simulation trials was compared with the SVR rate of the 
original study in order to confirm the ability of the model developed from short-term 
clinical data to predict the long-term clinical outcome (SVR/cure).  The time profile of 
model-predicted SVR also was examined in this study.  
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RESULTS  
    Modeling and simulation were performed according to the plan in Figure 4.1. In 
step 1, deterministic simulation using the mean parameter estimates obtained from 
the final population PK-PD/HCV viral dynamic model in chapter 3 showed that the 
inhibition fraction (INH) for patients with HCV genotype 1 ranged from 3% to 75% 
during a steady-state dosing interval, while INH for patients with HCV non-genotype 
1 ranged from 40% to 99% (Figure 4.2. (A)). The low inhibitory effect against HCV-1 
genotype 1 caused insignificant low viral reduction with approximately less than 1 
log10 HCV RNA decline (1 log corresponds to a 10-fold change in HCV RNA 
copies/mL) following by rebound to pre-treatment levels.  The strong inhibition effect 
against HCV non-genotype 1was sufficient to induce a decline in viral loads to 
undetectable HCV RNA levels at around 6 weeks of therapy (Figure 4.2. (B)). 
However,  simulated HCV viral loads  still demonstrated viral rebound after the 
termination of 48 weeks treatment, which indicated an unsuccessful long-term 
clinical outcome (absence of SVR).  
 RBV effectiveness (Eqn. 4.2.) was incorporated into the model in step 1 as RBV 
concentration data were not available (Figure 4.3.). RBV effectiveness, ρ, was 
simulated to mimic slow accumulation of RBV in plasma from 0 at time=0 to 50% 
maximum effect in t ≈ 4 week (Figure 4.4. (A)). Inclusion of an RBV effect was 
necessary to describe the viral load decline for patients with HCV genotype-1, but 
not for patients with HCV non-genotype-1. The addition of RBV effectiveness 
resulted in a noticeable effect on viral load decline, approximately 4 log10 HCV RNA 
decline from pre-treatment levels, for patients with HCV genotype 1, but viral load 
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was still did not reach undetectable levels (Figure 4.4. (B)). The RBV effect had a 
negligible influence on viral loads for patients with HCV non-genotype 1 who already 
showed a high degree of viral inhibition with PEG-INF (Figure 4.4. (B)). In addition, 
=implementation of a cure/virus-eradication boundary (Eqn. 4.7 – Eqn. 4.8) was able 
to remove the viral rebound after 48 weeks treatment, thereby successfully 
characterizing SVR (Figure 4.4. (B)). 
    The final PK-PD/HCV simulation of long-term clinical outcome during HCV 
treatment, evaluated using the deterministic approach, then was used for population 
modeling with 2 weeks of clinical data. The parameters of the model were estimated 
with good precision (Table 4.1.) The addition of RBV effectiveness to the model 
resulted in a significant decrease in objective function value, -10 (p < 0.05). In 
addition, although accounting for RBV effectiveness in the final model did not 
significantly change the parameter estimates associated with PEG-INF 
effectiveness, such as IC50 and γ, a 43.6 % increase for the estimate of δ, the death 
rate of infected hepatocyte (Table 4.2.), was observed. The goodness-of-fit 
assessment revealed that observed HCV measurements were well-described by the 
model without systematic bias (Figure 4.5.). Individual predictions by the final model 
corresponded to individual observations of HCV viral loads (Figure 4.6.). The viral 
load profiles generated in 200 simulations using the final model are presented in 
Figure 4.7. The majority of the observed HCV viral loads were within the range of the 
lower (2.5%) and upper (97.5%) percentiles of simulated viral loads.  
    Predictive performance of the final model from short-term clinical outcome to 
long-term clinical outcome (SVR) was assessed by Monte Carlo simulation for a 
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study design that included 48 weeks of treatment and 24 weeks of follow-up. The 
model was successfully qualified for further simulations given the fact that the 
predicted range of SVR matched well with the observed value in the original study 
(Figure 4.8.). The result of Monte Carlo simulations showed that approximately 80%, 
92% and 100% of predicted SVRs were reached at week 8, 12, and 20, respectively, 
of treatment (Figure 4.9)  
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DISCUSSION  
    The present study successfully demonstrated that a population model 
integrating host-viral-drug information from a short-term clinical study was able to 
predict the likelihood of a positive long-term clinical outcome for PEG-INF-based 
treatment of HCV infection. The key for this successful prediction of long-term 
clinical outcome was implementation of a physiologically-based viral eradication 
boundary in the viral kinetic model (Snoeck, Chanu et al. 2010) that connects 
clinically observed HCV viral dynamics to SVR. The viral kinetic model with 
incorporation of a cure boundary provides predictive information about whether a 
patient is likely to clear the virus 24 weeks after the cessation of therapy for a new 
drug.  
    In the present study, the impact of the ignorance of RBV effectiveness on 
simulation of viral load and estimating parameters associated with viral kinetic 
models when all patients received a combination therapy of PEG-INF plus RBV was 
addressed since the original study was a monotherapy study PEG-INF alone and 
information regarding RBV concentrations was lacking (Talal, Ribeiro et al. 2006). 
However, RBV in combination with IFN has been shown to increase the viral 
suppression obsereved with interferon alone, and to reduce relapse rates although it 
has minimal effect against HCV when administered as a monotherapy (Hill 1910). 
The mechanism by which RBV suppresses HCV when used with interferon has not 
been established clearly. In the present simulation study, RBV effectiveness 
evidenced a noticeable impact on viral decline of patients with HCV genotype-1, but 
not on that for patients with HCV non-genotype 1, an outcome that may be related to 
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the differential effectiveness of PEG-INF across different HCV genotypes. HCV 
genotype 1 has been shown to be associated with a lower rate of SVR compared 
with genotypes other than 1 (Nishimoto and Ellner 1983; Manns, McHutchison et al. 
2001; Fried, Shiffman et al. 2002). In chapter 3, it was observed that the mean IC50 
in patients with HCV genotype 1 was higher than that in patients with HCV non-
genotype 1 (0.55 vs. 0.16 µg/L), respectively), representing lower drug effectiveness 
in patients with HCV genotype 1. It also was reported previously that RBV had little 
effect on viral decay at low PEG-INF effectiveness, but had a significant effect at 
high PEG-INF effectiveness through enhancing the second-phase viral decay slope 
(Giannini, Bodini et al. 2010) which reflects the loss rate of infected cells (Neumann, 
Lam et al. 1998). Importantly, in the present study, the increase in the death rate of 
infected hepatocytes without a change in parameters associated with PEG-INF drug 
effectiveness when adding RBV effectiveness to the model was observed. 
Therefore, inclusion of RBV drug effectiveness in modeling and simulation for the 
combination therapy of PEG-INF plus RBV is important for accurate prediction of 
clinical outcome in patients with HCV genotype-1 or with other covariates that cause 
lower drug effectiveness to PEG-INF.  
    In summary, a growing number of studies in HCV are being conducted to 
develop direct-acting antiviral agents that interfere with specific steps in the HCV 
replication cycle for the treatment of chronic hepatitis C infection(De Francesco and 
Migliaccio 2005; Cheng, Gupta et al. 2011; Soriano, Vispo et al. 2011). Since 
Sheiner (Sheiner 1997) first proposed the learn-confirm paradigm of drug 
development, the method of modeling and simulation has played a key role in 
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learning phase for determining the optimal dose and contributed to expediting drug 
development process. Predicting long-term clinical outcome from short-term clinical 
studies will provide important insight into doses and dosing schedules that can be 
successful in the long-term treatment of HCV. 
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   Parameter                        Estimate                         RSE(%) 
 
Fixed effect 
      IC50 (µg/L)                                           0.507                           (15.5)                      
      γ                                                            2.97                            (14)        
      ta (day)                                                  5.6                             FIXED 
      ρmax                                                       0.5                             FIXED 
      S (hepatocytes/ml/day)                        61.7*103                     FIXED                       
      d (per day)                                            0.003                          FIXED 
      c (per day)                                            6.2                              FIXED 
      δ  (per day)                                           0.402                          (33.3)                      
      R0                                                         16.4                             (28.2)                      
Inter-individual variability  
      ω2  [δ] (%CV)                                                            107.2                                                     
      ω2  [IC50] (%CV)                                             61.7                                                    
Residual Variability  
      σ2 add (IU/ml)                                        0.08                              (9.18)                       
 
        
  
 
 
 
 
 
 
 
 
Table 4.1:  Final parameters of final population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model; IC50: the estimated PEG-INF 
concentration that results in a 50% inhibition of virion production, γ: Hill 
coefficient on drug effect, ta: accumulation timescale of RBV, ρmax: RBV 
maximum drug effect (%), S: hepatocyte production rate constant, d: 
hepatocyte death rate constant, c: virion elimination rate constant, δ: infected 
cell death rate constant, R0: basic reproductive number, RSE: relative standard 
error, it reflects the precision of the estimated parameters.  
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Parameter with RBV PD model               without RBV PD model                    
 
OFV                                             -275.65                                    -265.60 
IC50 (µg/L)                                   0.507                                         0.542  
 γ                                                  2.97                                           3.03 
 ta (day)                                        5.6                                              __ 
 ρmax                                              0.5                                             __ 
  δ  (per day)                                 0.402                                         0.28                    
  R0                                                16.4                                          17.4  
Inter-individual variability  
 ω2  [δ] (%CV)                                                 107.2                                       132.3         
 ω2  [IC50] (%CV)                                     61.7                                         65.3   
Residual Variability  
σ2 add (IU/ml)                                  0.08                                          0.08                      
Table 4.2.: Summary of two population pharmacokinetic-
pharmacodynamic/HCV viral dynamic models 
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Figure 4.2: Inhibition fraction (A) and HCV viral load (B) from a simulation 
study in Berkeley Madonna, using a developed PK-PD/HCV viral dynamic 
model from data including only pegylated interferon concentrations. Solid 
lines: profile for patient with HCV genotype 1 (IC50 = 0.55 µg/L); dot lines: 
profile for patient with HCV non-genotype 1 ( IC50 = 0.16 µg/L) 
 
 
 
A 
B 
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Figure 4.3.: Scheme depicting the modified pharmacokinetic-
pharmacodynamic/HCV viral dynamic model of PEG-IFN + RBV; INH: inhibition 
fraction (%) on viral production by PEG-INF, ρ: RBV drug effect. It assumes that 
RBV renders a fraction of newly produced virions non-infectious, ρmax: maximum 
RBV drug effect, ta: RBV accumulation timescale 
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Figure 4.4.: Inhibition fraction (A) and HCV viral load (B) from a simulation 
study in Berkeley Madonna, using a developed PK-PD/HCV viral dynamic 
model from the combination of pegylated interferon and ribavirin concentrations. 
Solid lines: profile for patient with HCV genotype 1 (IC50 = 0.55 µg/L); dot lines: 
profile for patient with HCV non-genotype 1 (IC50 = 0.16 µg/L) 
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Figure 4.5.: Goodness of Fit plots of population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model. Different symbols indicate each subject.  
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Figure 4.6.: Individual plot of population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model; blue line: Empirical Byes 
Estimate individual prediction, red line: population prediction, points: 
observation 
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Figure 4.7.: Visual predictive Check plot of population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model. 
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Figure 4.8.: Observed (blue vertical line) and model-predicted SVR (grey 
histogram) from 1000 simulation trials, using the developed model from the first two 
week data 
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Figure 4.9.: Model-predicted percentage patients with undetectable HCV RNA 
viral loads over time 
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CHAPTER 5 
CONCLUSIONS 
 
      The central aim of this dissertation project was to characterize and quantify the 
impact of in vivo pharmacodynamics parameters such as IC50 and slope parameter γ 
of concentration-response, on clinical outcomes in HIV and HCV treatment. Although 
in vitro analysis of antiviral activity, which evaluated by measuring viral replication in 
the presence of various concentrations of the relevant drug, have commonly been 
used to compare drug potency, it is challenging to directly establish a relationship 
between in vitro pharmacodynamics and virological responses. In vivo 
pharmacologic response is often poorly understood since several major 
impediments exist. First, the inhibition of viral replication or viral production by the 
relevant drug is not directly able to measure in clinical studies, but viral load declines 
from the baseline are the important surrogate marker to assess the pharmacologic 
response to the drugs in HIV and HCV treatment. Therefore, in vivo values for IC50 
and γ are not able to obtain solely by a sigmoid Emax model as the model is used for 
in vitro study. Second, there are undefined confounding factors such as patient or 
viral specific covariates that would result in inter-patient variability in 
pharmacokinetics and pharmacodynamics. Thirdly, the emergency of drug 
resistance can alter the viral susceptibility to the drug, thereby eventually leading to 
fail achieving the virological response. The complicated nonlinear relationships and 
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interactions among all these factors and the long-term responses may also reduce 
the detectability of the effect of a single factor on the response. To address the 
impact of in vivo pharmacodynamic parameters on clinical outcomes in HIV and 
HCV treatment, modeling and simulation approach for pharmacokinetic-
pharmacodynamic/viral dynamic model was employed to overcome the major 
impediment.   
 The underlying hypothesis of this doctoral dissertation research was that in vivo 
pharmacodynamic parameters are important clinical predictive keys to assess 
clinical outcomes in HIV and HCV treatment. This hypothesis was examined by a 
series of modeling and simulation experiments described below:  
 
1. Characterize the impact of in vivo slope parameter γ of concentration-response on 
the clinical outcome in HIV treatment (Chapter 2). The integrated population 
pharmacokinetic-pharmacodynamic/HIV viral dynamic models were used to test the 
hypothesis that higher γ contributed to larger log10 decline from the baseline in HIV-1 
RNA and  higher patient proportion (%) with 50 copies/mL at 48 weeks. Before 
collecting clinical data, model-based simulation was performed to evaluate the 
impact of γ on the rate of viral decay and the log10 change from the baseline in HIV-1 
RNA. Thereafter, we developed a population PK-PD/HIV viral dynamic model to 
estimate in vivo IC50 and γ and examined the relationship between in vivo 
pharmacodynamics parameters and the log10 declines from the baseline in HIV-1 
RNA, using phase IIa short-term monotherapy for an investigational Non-Nucleoside 
Reverse Transcriptase Inhibitor (NNRTI) drug. Finally, we performed Monte Carlo 
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simulation in order to evaluate the possible impact of γ on the long-term clinical 
outcome in combination regimen of Atripla. The probability distribution of patients (%) 
with HIV-1 RNA <50 copies/ ml at week 48 was examined by 100 trial simulations 
using a population PK-PD/HIV viral dynamic model with a dataset including 1000 
subjects. 
 
2. Examine whether pharmacodynamic parameters from the short-term clinical 
outcomes are associated with Hepatitis C virus (HCV) therapeutic outcomes and 
whether patient-specific covariates or viral factors are associated with their inter-
individual variability (Chapter 3). The population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model was employed in order to test the 
hypothesis that in vivo pharmacodynamic parameters estimated from the short-term 
clinical outcome were strongly related to HCV therapeutic outcome; namely, patients 
who achieved sustained virological response (SVR) had lower in vivo IC50 and high γ. 
Also we hypothesized that there were high inter-variability on estimates of in vivo 
IC50 and γ since the various clinical outcomes for patients who received pegylated 
interferon α-2b based treatment. Thus, we also examined patient-specific covariates 
and viral factors that may be associated with inter-patient variability on estimates of 
in vivo IC50 and high γ.  
 
3. Investigate whether population pharmacokinetic-pharmacodynamic/viral dynamic 
model developed from the short-term clinical data is able to predict the long-term 
HCV therapeutic outcomes. Data was obtained from a previous publication which 
143 
 
included 24 HCV/HIV-co-infected patients administered PEG-IFN α-2b 1.5 µg/kg 
once weekly and RBV 1000-1200 mg daily for up to 48 weeks. The individual 
concentration and HCV RNA measurement-time profiles were used to develop a 
sequential population pharmacokinetic-pharmacodynamic/HCV viral dynamic model 
using NONMEM. 1000 simulation trials were performed and the sustained virologic 
response (SVR) of the original study was compared with the model-predicted SVRs. 
Simulation of RBV effectiveness was also integrated to the model as ribavirin 
concentration data were not available. In addition, virus-eradication boundary was 
implemented in the model to describe SVR of simulation results. The hypothesis 
underlying this aim was that the population 
pharmacokinetic/pharmacodynamics/HCV viral dynamic model developed from the 
short-term clinical outcome was able to predict the reasonable likelihood of SVRs 
when virus-eradication boundary was implemented to the model. Also we also 
hypothesized that ribavirin drug effectiveness was significant to achieve the SVR for 
patients who showed low drug effectiveness from the pegylated interferon treatment.  
 
The impact of in vivo slope parameter γ of concentration-response on the 
clinical outcomes in context of non-compliance and drug resistance in HIV 
treatment (Chapter 2).   
 In vitro analysis of antiviral activity is typically accomplished by measuring viral 
replication in the presence of various concentrations of the relevant drug. 
Concentration-response curves can be analyzed with the sigmoid Emax model. IC50, 
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the concentration that inhibits replication by 50%, is the most widely used measure 
of drug inhibition. IC50 is a useful measure for most drugs, but it may not be ideal for 
examining antiviral efficacy for anti-HIV-1 drugs since 50% inhibition on replication is 
small compared with the six-log-target level of inhibition required to completely 
suppress replication in a typical patient (Shen, Rabi et al. 2009). In addition to IC50, 
a second critical factor in determining drug efficacy is the drug concentration that 
can be achieved in vivo. This is reflected in the IQ, which is the ratio of trough 
plasma drug concentration achieved during standard dosing to the IC50 (Ellner and 
Neu 1981; Neu and Ellner 1983). Although IQ captures two critical dimensions of 
antiviral activity, it still neglects a critical third parameter, γ. This parameter 
measures the steepness of the concentration-response curve and is analogous to 
the Hill coefficient (Hill 1910), which reflects cooperativity in the binding of multiple 
ligands to a receptor. It was not well known whether γ is a shape factor that only 
improves the mathematical fit of a model or whether γ is a pharmacodynamic 
parameter that can independently characterize antiretroviral (ARV) drug 
effectiveness. Shen L. et. al. first addressed that each ARV class has a 
characteristic γ in in vitro experiments: nucleoside reverse transcriptase inhibitors 
and integrase inhibitors have γ of ~1 while non-nucleoside reverse transcriptase 
inhibitors, fusion inhibitors have γ of ~2, and protease inhibitors have γ between 1.81 
and 4.53 (Shen, Peterson et al. 2008). However, so far, the influence of γ of ARV 
drugs on in vivo efficacy has not been shown.  
In order to examine the influence of in vivo γ on clinical outcome, an 
integrated pharmacokinetic-pharmacodynamic/HIV viral dynamic model was applied. 
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At first, the impact of γ on viral load decline was evaluated by model-based 
simulation before clinical data were collected. This in silico study also allowed 
efficient exploration of the influence of the γ on clinical efficacy with consideration of 
non-compliance and the alteration of drug susceptibility due to the emergence of 
drug resistance. This study showed that higher γ results in larger log10 decline in 
HIV-1 RNA when a drug is well susceptible to HIV virus, but once drug effectiveness 
decreases, possibly due to development of drug resistance, smaller values of γ 
produce a larger decline in viral load. Secondly, we characterized the impact of γ on 
viral load decline, using phase IIa short-term monotherapy study for an 
investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) drug. This 
population modeling addressed that γ does not only improve model fitting, but also 
appropriately relates the pharmacodynamic parameters to the log10 change from the 
baseline, which is the most frequently used surrogate marker in phase IIa short-term 
monotherapy studies, by the proportional relationship between γ and log10 change 
from the baseline and disproportional relationship between IC50 and log10 change 
from the baseline.  IC50 alone as a pharmacodynamics parameter was not able to 
appropriately describe the drug effect on the log10 change from the baseline. Lastly, 
Monte Carlo simulations were conducted in order to investigate the impact of γ on 
long-term combination regimen of Atripla (efavirenz (EFV)/emtricitabine 
(FTC)/tenofovir disoproxil fumarate (TDF) 600mg/200mg/300mg). The probability 
distribution of patients (%) with HIV-1 RNA <50 copies/ ml at week 48, performed by 
100 trial simulations using a population PK-PD/HIV viral dynamic model with a 
dataset including 1000 subjects showed that higher γ contributes to higher 
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percentage of patients with HIV-1 RNA <50 copies/ ml at week 48. Also, higher γ 
results in longer viral suppression at undetectable levels. However, we found γ 
contributes insignificantly once the development of drug resistance occurs.  
Overall, these results demonstrated that higher γ can contribute to achieve 
better clinical outcomes in short-term and long-term clinical studies. However, the 
impact of γ is insignificant once the emergence of drug resistance occurs clinically.  
 
Use of population pharmacokinetic-pharmacodynamic/ Hepatitis C virus viral 
dynamic model to examine the association between pharmacodynamic 
parameters from short-term clinical outcomes and Hepatitis C virus (HCV) 
therapeutic outcomes (Chapter 3). 
The HCV is a leading cause of chronic liver disease and gives rise to a major 
public health problem globally. The primary goal of therapy for chronic HCV is to 
achieve a sustained virologic response (SVR), defined as an absence of detectable 
HCV RNA 24 weeks after the completion of antiviral treatment. For decades, 
pegylated interferon (PEG-IFN) administered in combination with ribavirin (RBV) for 
48 weeks has been often referred to as standard of care (SOC) for chronic hepatitis 
C (CHC). However, the therapy does not universally result in cure in all patients who 
undergo treatment. Also, treatment with the combination therapy carries the risk of 
serious side effects that are dominated by fatigue, influenza-like symptoms, 
hematologic abnormalities, and neuropsychiatric symptoms (Fried 2002).  
147 
 
The aim of this study was to examine whether pharmacodynamic parameters 
from the short-term clinical outcomes are associated with HCV therapeutic outcomes 
(SVR) and whether patient-specific covariates or viral factors are associated with 
their inter-individual variability, using an integrated population pharmacokinetic-
pharmacodynamic /HCV viral dynamic model. The sequential population PK-PD 
/HCV viral dynamic model was developed with NONMEM using published data from 
which included PEG-IFN α-2b concentrations and HCV RNA measurements during 
weeks 1 and 2, and patient baseline characteristics. A sigmoid Emax model was used 
to link the PK and HCV viral dynamic model.  IC50 and the Hill coefficient (γ) were 
estimated in the PD component of model. The nonparametric Mann-Whitney U test 
was used to assess the significance of difference in individual post-hoc estimates 
(empircal Bayes estimates) of parameters between patients who attain SVR and 
those who do not (NR). The population PK-PD/HCV viral dynamic model adequately 
described the clinical data as assessed by visual inspection of diagnostic plots, 
precision of the parameter estimates, visual predictive checks and bootstrapping. 
The goodness-of-fit of the model increased significantly when γ was included (P < 
0.001). However, inter-individual variability on γ was not statistically significant. The 
model showed that individual parameter estimates for IC50 and the death rate of 
infected cell (δ) were significantly different between SVRs and NRs. The PK 
parameters and δ were not influenced by covariates, but IC50 in patients with HCV 
genotype-1 was higher than that in those with HCV non-genotype 1 (0.55 µg/L vs. 
0.16 µg/L). The present study demonstrated no difference in γ between SVRs and 
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NRs. Therefore, IC50 alone from early data is sufficient to describe drug effect for 
predicting clinical outcomes.  
 
Prediction of long-term HCV treatment outcome using a population 
pharmacokinetic-pharmacodynamic/HCV viral dynamic model developed from 
short-term therapy (Chapter 4).  
Early detection of non-SVR is of major importance to avoid unnecessary 
treatment-related morbidity. Also a model that accurately predicts long-term clinical 
outcome is critical in comparing drug efficacy among varying therapeutic regimens in 
drug development. It is unknown whether a PK-PD/viral dynamic model developed 
using available data obtained from short-term therapy is capable of predicting long-
term clinical outcome.  
The aim of this study was that the probability of model-predicted SVR was 
compared by Monte Carlo simulation with the observed SVR in order to evaluate 
whether the population pharmacokinetic-pharmacodynamic/viral dynamic model 
developed from early clinical data with PEG-INF-based treatment is able to 
reasonably predict the long-term clinical outcome. 
Before the Monte Carlo simulation to assess the predictability of long-term 
clinical outcomes using the developed PK-PD/HCV viral dynamic model in Chapter 3 
the model was first implemented in Berkeley Madonna (Version 8.3.18) (Koblin, 
Husnik et al. 2006) in a deterministic setting. In this stage, the impact of RBV drug 
effect on viral load decline was also evaluated since RBV concentration data were 
not available during modeling building in Chapter 3. Inclusion of RBV drug effect to 
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the model had negligible effect on simulation of viral loads for patients with HCV 
non-genotype 1 who already showed high inhibition with PEG-INF, but showed a 
noticeable effect on viral load decline, approximately 4 log10 HCV RNA decline from 
pre-treatment levels, for patients with HCV genotype 1, but viral load was still not 
able to reach undetectable levels. In addition, virus-eradication boundary (Snoeck, 
E. et al. 2010) was implemented in the model to describe SVR of simulation results 
and show adequately characterized SVR.  
The final model evaluated using Berkeley Madonna software was then 
implemented in NONMEM in a Monte Carlo fashion, which include random noise 
terms for both assay error and inter-individual variability. For the Monte Carlo 
simulation study, population pharmacokinetic-pharmacodynamic/HCV viral dynamic 
model was first fit to HCV viral load data during 2 week of a clinical study (Talal, 
Ribeiro et al. 2006) using nonlinear mixed effects modeling methodology. Parameter 
estimates from the two models (one including a PD model of RBV and the other not 
including the PD model of RBV) were compared in order to investigate how the 
inclusion of a PD model for RBV would impact other parameter estimates. The 
addition of RBV effectiveness to the model resulted in a significant decrease in 
objective function value. In addition, although accounting for RBV effectiveness into 
the final model did not significantly change the parameter estimates of PEG-INF 
effectiveness, such as IC50 and γ, a 43.6 % increase for the estimate of δ, the death 
rate of infected hepatocyte was observed. 
After the model validation of population pharmacokinetic-
pharmacodynamic/HCV developed from first 2 weeks of data from the clinical study, 
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1000 trials were stochastically simulated using Monte Carlo simulation with 2-levels 
of random effects estimated from the final model: inter-individual variability and 
residual variability. Simulation of long-term therapy using the developed model showed 
that the observed SVR outcome falls within the range of model-predicted SVR outcomes. 
Collectively, we successfully demonstrated that a population model 
integrating host-viral-drug information from a short-term clinical study was able to 
predict the likelihood of long-term clinical outcome for PEG-INF based treatment in 
HCV infection. 
 
Significance, study limitations and future directions 
    In order to enhance the confidence on results of this dissertation research, we 
will, in this section, discuss what study limitations are and how to prompt a number 
of proposed future studies regarding the impact of in vivo pharmacodynamics 
parameters on predicting clinical outcomes in HIV and HCV and identifying patient 
specific covariate factors that would explain low drug response with approach of 
modeling and simulation, using a combination of drug-disease-clinical trial models. 
These topics are detailed below.  
 
Is in vivo γ important to characterize drug effectiveness in a clinical setting?      
(Chapter 2) 
 
The instantaneous inhibitory potential (IIP), a novel index of in vitro antiviral activity 
developed by Shen et al (Shen, Peterson et al. 2008; Shen, Rabi et al. 2009; Shen 
and Siliciano 2010), and this group suggests the IIP is a more accurate 
representation of intrinsic antiviral activity than IC50 or inhibitory quotient because the 
151 
 
IIP takes into account the value of γ. In our dissertation project, we further examined 
the significance of in vivo γ obtained from clinical data and showed γ may not be a 
key pharmacodynamic parameter to determine the clinical outcome in HIV infection 
unlike its observation from in vitro experiments.  
 First, our estimation of in vivo γ of a NNRTI drug in this project was around 1 
while the reported average value of γ of NNRTI drugs from in vitro experiments was 
approximately 2. Therefore, we did not find that the NNRTI drug has higher γ in a 
clinical setting. It is still needed to examine in vivo γ of other ARV classes, especially 
protease inhibitors, which values of γ for indinavir, saquinavir and darunavir were 
high up to 4 in in vitro experiments (Shen, Peterson et al. 2008). Estimating in vivo γ 
requires clinical data of monotherapy in order to relate pharmacodynamic effect with 
viral load decline from a single ARV drug, but it is challenge to find such clinical 
efficacy monotherapy study data since ethically patients with HIV-1 infection are 
given with combination therapy during the drug development (except some phase IIa 
study) in order to reduce the chance for the development of drug resistance. 
    Secondly, the significance of in vivo γ needs to be examined at situations of 
non-adherence or the emergence of drug resistance, which are the most important 
factors to cause treatment failure during long-term treatment (Chesney, Ickovics et al. 
1999; Bangsberg, Perry et al. 2001; Shafer and Schapiro 2005). The examination of 
the relationship between pharmacodynamic parameters and long-term clinical 
outcome is currently not possible to investigate from clinical studies performed 
during the drug development. First, long-term clinical studies are designed as 
combination therapy, which suggest that there may be unknown interactions of 
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pharmacokinetic or pharmacodynamics properties among drugs in a combination 
therapy. During the long-term clinical study, it is not to collect intensive 
concentrations of all administered drugs and viral load measurements, and therefore 
it is difficult to account the potential interactions of pharmacokinetics or 
pharmacodynamics among administered drugs. Secondly, non-adherence is often 
observed during long-term treatment and it further causes the low therapeutic 
outcome. For these reasons, it is a challenge to study the impact of in vivo γ on long-
term clinical outcome.  
    The simulation studies performed using knowledge based on a combination 
therapy of Atripla in this dissertation project suggested that the higher in vivo γ would 
provide benefits for patients with poor non-adherence since our simulation studies 
showed higher in vivo γ contributes to faster viral decline and longer duration of viral 
suppression under the limit of detection for patients who experience poor non-
adherence. However, once the emergence of drug resistance occurs, the impact of 
in vivo γ was not significant and all simulations experienced viral rebound regardless 
the values of γ. This observation from the simulation studies confirmed IC50 fold-
change is much bigger than the fold-change on in vivo γ, and therefore the impact of 
in vivo γ is small on clinical outcome once the drug resistance occurs.  
 Collectively, the impact of in vivo γ would not significantly contribute to predict 
clinical outcome in HIV infection unlike Shen et al addressed it in vitro experiments.  
 
The application of stochastic models to describe the evolution of viral 
population, eventually contribution to drug resistance (Chapter 2)  
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   Antiretroviral therapies for HIV infection often fail to sustain virological 
responses because of the emergence of multidrug resistant strains of HIV (Perrin 
and Telenti 1998; Vandamme, Van Laethem et al. 1999). In this present study, we 
simplified the emergence of drug resistance against EFV with a simple non-linear 
regression in simulation studies. However, in reality, the viral genetic evolution, 
driven by the drug pressure, is intrinsically a stochastic process (Nijhuis, Boucher et 
al. 1998).  A very high genetic variability of HIV-1 leads to the generation of many 
variants of HIV-1 in a single infected patient in a brief time span (Mansky and Temin 
1995; Anderson, Rodrigo et al. 2001). Compete eradication is not feasible with the 
current treatment options in HIV infection thereby drug–resistance variants can 
ultimately develop in patients even under Highly Active Antiretroviral Therapy 
(HAART) pressure. Therefore, development of sophisticated mathematical models 
characterizing the drug development and its appreciation to predict clinical outcome 
is important.   
 Several mathematical models have been investigated for the description of the 
development of drug resistance in the human body. A previous study made an 
attempt to model the efficacy as a time varying term using a linear decreasing 
function of the phenotypic-fold change (Huang, Rosenkranz et al. 2003). However, 
this model is still insufficient to characterize the stochastic viral evolution. Multiple-
strain model (i.e. different equations for different viral mutant species) was 
developed to explain the drug resistance onset, where the constant terms for drug 
efficacy have different values for each mutant species (Phillips, Youle et al. 2001). 
However, the drawback of this method is that viral population is simply divided in a 
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few additional equations that represent resistant and susceptible viral populations. A 
recent study adopted the instant probabilities of drug resistance that can be 
estimated by means of functions trained from in vitro phenotypes, with a roulette-
wheel-based mechanisms of resistant selection for the stochastic predator-prey 
modeling for viral dynamics (Prosperi, D'Autilia et al. 2009). Even though this study 
made great advance on stochastic approach of viral dynamics, it assumed 
independence in the mutation emergence. However, many single mutations have 
been linked to resistance to 1 or more drugs and also show some preferential 
pathways that explain conditional dependencies in the accumulation of mutations 
towards drug resistance. It is unknown about how these mutations accumulate 
because of a lack of sufficient longitudinal data and in clinical samples, complex 
mutational patterns are found rendering interpretation difficult. Understanding the 
evolutionary pathways to HIV drugs is important for the design of effective 
therapeutic strategies. A mutagenetic mixture tree model introduced by 
Beerenwinkel N et al (Beerenwinkel, Rahnenfuhrer et al. 2005; Beerenwinkel, 
Rahnenfuhrer et al. 2005) highlighted preferential pathways that explain conditional 
dependencies in the accumulation of mutations towards drug resistance. The 
benefits of this modeling method is allowing to estimate the distance of a resistant 
virus population to escape from drug pressure and further to investigate the 
expected waiting time of each mutation (Beerenwinkel, Daumer et al. 2005).  
    The incorporation of these mathematical/statistical models for the drug 
resistance into a pharmacokinetic-pharmacodynamic/viral dynamic model will 
improve the quality of models in order to examine the impact of in vivo 
155 
 
pharmacodynamics parameters on clinical outcome at situations of the emergence 
of drug resistance.  
 
The role of in vivo pharmacodynamic parameters for identifying patient 
specific covariate factors that would explain low drug response and for a new 
combination therapy in HCV infection (Chapter 3) 
   This dissertation project addressed patients with HCV genotype-1 infection has 
higher in vivo IC50 than that for patients with non-HCV genotype 1 infection. This 
finding corresponds to clinical observation of low rate of SVR in patient who infected 
with HCV genotype-1 (Manns, McHutchison et al. 2001; Fried, Shiffman et al. 2002; 
McHutchison, Lawitz et al. 2009). We also examine the relationship between African 
American and pharmacodynamic parameters since SVR rates for African American 
who treated with pegylated interferon and ribavirin for 48 weeks are substantially 
lower (Muir, Bornstein et al. 2004; Conjeevaram, Fried et al. 2006).  However, we 
did not find the impact of race on inter-individual difference in pharmacokinetic and 
pharmacodynamics/viral dynamic parameters in this study. This would be the small 
number of patients in this study, which the total number of patients is 24 and 12 of 
them are African American. Therefore, it is essential to examine the reason of low 
SVR rate of African American, using an integrated population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model with the large number of patients.  
    Currently, there are endeavors in the development of direct-acting antiviral 
agents (DAAs) that interfere with specific steps in the HCV replication cycle for the 
treatment of chronic HCV infection (De Francesco and Migliaccio 2005; Cheng, 
156 
 
Gupta et al. 2011; Soriano, Vispo et al. 2011). In 2011, two direct-acting HCV drugs, 
Boceprevir (Merck) and Telaprevir (Vertex)  were approved by the FDA for use in 
combination with PEG-INF α and RBV for the treatment of genotype-1 chronic HCV. 
Boceprevir is a peptidomimetic nonstructural 3 (NS3) protease inhibitor that forms a 
covalent reversible complex with the NS3 protease in vitro (Malcolm, Liu et al. 2006). 
Telaprevir is also the NS3 protease inhibitor and has shown significantly higher rates 
of SVR than the standard of care in patients with genotype 1 infection (Hezode, 
Forestier et al. 2009; McHutchison, Everson et al. 2009). It has not known viral 
dynamic models for this new combination therapy with a NS3 protease inhibitor. It 
will be important to investigate whether there is additive pharmacodynamics effect 
between the combination treatment of pegylated interferon and ribavirin, and a NS3 
protease inhibitor. The development of an integrated population pharmacokinetic-
pharmacodynamic/HCV viral dynamic model for this new therapy will be valuable to 
examine pharmacokinetic or pharmacodynamics parameters to predict SVR.  
 
 
 
 
 
 
 
 
 
 
157 
 
APPENDIX 
 
A. NONMEM CODE  
I. Population PK-PD/HIV viral dynamic model developed using data 
from a phase IIa short-term monotherapy study of an investigational 
NNRTI drug (Chapter 2) 
$PROB1 SEQUANTIL PK-PD/HIV VIRAL DYNAMIC MODEL  
;Units: Time (day) 
;PD Volume (uL) 
;Viral load (log10 count/mL=log10 count/uL+3), 
$DATA v_dyn_v1.csv IGNORE='C' 
$INPUT C STDY=DROP ID DOSE TIME EVID AMT ADDL II SS DV MDV CMT 
BSVL SCL SV2 SKA SQ SV3 SLAG  
 
$SUBROUTINE ADVAN6 TOL=5 
$MODEL 
  COMP=(ABS,DEFDOSE) 
  COMP=(CENT) 
  COMP=(PERI)  
  COMP=(UCELL)   ;UNINFECTED CELLS 
  COMP=(ACELL)   ;ACTIVELY INFECTED CELLS 
  COMP=(LCELL)   ;LATENTLY INFECTED CELLS 
 
$PK 
  KA = SKA 
  V2 = SV2 
  CL = SCL 
  V3 = SV3 
  Q = SQ 
  ALAG1 = SLAG 
  F1 = 1 
  IF(DOSE.EQ.800) F1= 0.703 
 
  IC50  =THETA(1)*EXP(ETA(1)) 
  RR0   =THETA(2)     ; reproductive ratio before treatment 
DA0   =THETA(3)     ;DA=actively infected cell death rate  
D     =0.006/24         ;uninfected cell death rate 
  DL    =0.03/24                    ;latently infected cell death rate 
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AL  =0.036/24                    ;AL rate of conversion from latently to  
                                          ;actively infected at Baseline 
  POVC  =35.4               ;ratio of birth to death rate of virus 
  QA    =0.97                 ;fraction of infected cells actively infected 
  QL    =0.029               ;fraction of infected cells latently infected    
  SL    =THETA(4)*EXP(ETA(3)) ; slope on INH 
  IF(SL.GT.5) EXIT 1 100 
  LOGV0=BSVL+ETA(2) 
  V0=10**LOGV0/1000 
 
;;;;;;;;; initialize each compartment to pre-treatment equilibrium ;;;;;;;;;;;;;;;;;;;; 
 
  BETA=(RR0-1)*D/V0  ; set beta from RR0 
  LAMBDA= RR0*D*DA0/BETA/POVC/(QA+(AL*QL/(AL+DL))) 
 
  INIA=V0/POVC 
  A_0(5)=INIA 
  INIL=QL*LAMBDA*(1-1/RR0)/(AL+DL) 
  A_0(6)=INIL 
  INIU=LAMBDA/RR0/D 
  A_0(4)=INIU 
   
 
$DES 
  DADT(1) = -KA*A(1)                             
  DADT(2) = (KA*A(1)+Q*A(3)-Q*A(2)-CL*A(2))/V2   
DADT(3) = Q*(A(2)-A(3))/V3        
              
INH = A(2)**SL/(A(2)**SL+IC50**SL) 
 
DADT(4) = LAMBDA-(1-INH)*BETA*V*A(4) - D*A(4)              
;uninfected cells 
DADT(5) =  QA*(1-INH)*BETA*V*A(4) - DA0*A(5) + AL*A(6)  
  ;actively infected cells 
DADT(6) =  QL*(1-INH)*BETA*V*A(4) - DL *A(6) - AL*A(6)  
  ;latently infected cells 
  V=POVC*A(5)     ;virus level approximation 
 
 
$ERROR 
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  IPRED = 0 
  IF (A(5).GT.0) IPRED=LOG10(POVC*A(5))+3 ;DV is log10(VL in copies/mL) 
  W=1 
  IRES=DV-IPRED 
  IWRES=IRES/W 
  Y=IPRED+ERR(1) 
 
$THETA 
  (0,82)           ;IC50 
  (14 FIX )         ;R0 
  (0.0413 FIX)     ;DA0 
  (0,2,5  )         ;slope on INH 
 
$OMEGA  
   1               ;IC50 
   0.0169 FIX       ;V0 
   0.03              ;slope   
 
$SIGMA  
   0.05 
 
$ESTIMATION MAXEVAL=9999 PRINT=2 SIG=3 METHOD=1 
MSFO=INTERM.MSF NOABORT 
$COVARIANCE PRINT=E MATRIX=S 
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II. Population PK-PD/HIV viral dynamic model used for Monte Carlo 
simulation for long-term clinical outcome of Atripla (Chapter 2, 
Figure 2.8) 
 
$PROBLEM COMBINATION THERAPY SIMULATION  
 ; scenario drug resistance to EFV, slope of EFV =2  
 
$INPUT ID DRUG=DROP TIME EVID AMT ADDL II CMT DV MDV  
$DATA VLdata4.csv  IGNORE= C 
$SUBROUTINE ADVAN13 TOL=9 
$MODEL 
 
 COMP = (DEPOT1)                     ; COMP 1 
 COMP = (DEPOT2)                     ; COMP 2 
 COMP = (DEPOT3)                     ; COMP 3 
 COMP = (CENT1)                      ; COMP 4 
 COMP = (CENT2)                      ; COMP 5 
 COMP = (CENT3)                      ; COMP 6 
 COMP = (PERI2)                       ; COMP 7 
 COMP = (PERI3)                        ; COMP 8 
 COMP = (TCELL)                      ; COMP 9                    
 COMP = (ACELL)              ; COMP 10 
 COMP = (LCELL)                      ; COMP 11 
 COMP = (DCELL)                ; COMP 12 
 COMP = (VIRUS)                      ; COMP 13 
 
$PK 
 
;;;;;;;;;  EFV population PK ;;;;;;;;;;;;;;;;;; 
 
 F1=1*EXP(ETA(1)) 
 V1 = THETA(1)     
 CL1 = THETA(2)  
 KA1 = THETA(3) 
 K1 = CL1/V1 
 
;;;;;;;;;; FTC population PK ;;;;;;;;;;;;;;;;;; 
 
 KA2 = THETA(4)*EXP(ETA(2))    
 VC2 = THETA(5)   
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 CL2 = THETA(6)*EXP(ETA(3))   
 Q2 =  THETA(7)    
 VP2 =  THETA(8)   
 KEFTC = CL2/VC2 
 K12FTC = Q2/VC2 
 K21FTC = Q2/VP2 
  
 ;;;;;;;;; TDF population PK ;;;;;;;;;;;;;;;;;; 
 
 VC3 = THETA(9)*EXP(ETA(4))     
 CL3 =  THETA(10)*EXP(ETA(5))    
 Q3 = THETA(11)    
 VP3 = THETA(12)    
 KE = CL3/VC3 
 KA3 = KE 
 K12 = Q3/VC3 
 K21 = Q3/VP3 
  
 IC50EFV = THETA(13) 
 IC50FTC = THETA(14) 
 IC50TDF = THETA(15) 
  
 TA2=20*24  
; EFV resistance accumulation timescale (day) 
; 20 days need to reach the highest IC50 fold change  
; since the EFV resistance occurs 
 
 EFV_IC50_FC_MAX = 40 ; maximum EFV IC50 fold change assumes 40.  
 IC50EFV_MAX = IC50EFV*EFV_IC50_FC_MAX 
 
 IF (TIME.GT.30*24) THEN    ; 30 days is the time EFV resistance begins 
 IC50EFV = IC50EFV_MAX*(1-EXP(-TIME/TA2)) 
 ELSE 
 IC50EFV = IC50EFV 
 ENDIF 
 
 ;;;; LITERATURE VALUES FROM FUNK(2001)'S PAPER (TABLE 1) ;;;;;; 
 
 D = 0.01/24    ; death rate of uninfected cell,  0.001 ~ 
0.01 PER DAY 
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 LABMDA = 1400/24     ; production rate of uninfected cell, 
CELLS/ML*D  
 BETA = 2*(10**(-8))      ; infection rate 2*10**(-8) ~ 3*10**(-7), 
CL/VIRION 
 PP = 500/24     ; viral production rate 
 C = 5/24     ; viral clearance rate 
 AA1 = 0.5/24     
 ; death rate constant of actively infected cell, 0.2~0.7 PER DAY 
 AA2 = 0.01/24     
 ; death rate constant of latently infected cell, 0.0005 ~ 0.004 PER DAY 
 AA3 = 0.03/24     
 ; death rate constant of defectively infected cell, 0.001 ~ 0.03 PER DAY 
 Q1= 0.99      
 ; FRACTION OF NEWLY INFECTED CELLS THAT BECOME ACTIVELY 
INFECTED CELLS 
 Q2 = 0.09      
 ; FRACTION OF NEWLY INFECTED CELLS THAT BECOME  
 ;LATENTLY INFECTED CELLS  
 Q3 = 0.01      
 ; FRACTION OF NEWLY INFECTED CELLS THAT  
 ;BECOME DEFECTIVELY INFECTED CELLS 
 ALPHA = 0.036     
 ; ACTIVATION RATE CONSTANT OF LATENTLY INFECTED  
 ; CD4+ CELLS 
 
 RR0 = BETA*LABMDA*PP/(AA1*D*C)*(Q1 + Q2*(ALPHA/(ALPHA + AA2))) 
 ; basic reproductive ratio 
 
;;;;;;;;; initialize each compartment to pre-treatment equilibrium ;;;;;;;;;;;;;;;;;;;; 
 
 INIT_T = LABMDA/(D*RR0) 
 A_0(9) = INIT_T 
 INIT_A = (RR0-1)*D*C/(BETA*PP) 
 A_0(10) = INIT_A 
 INIT_L = INIT_A*(AA1/Q1)/((ALPHA + AA2)/Q2 + ALPHA/AA1) 
 A_0(11) = INIT_L 
 INIT_DD = INIT_L*((ALPHA + AA2)/Q2)/(AA3/Q3) 
 A_0(12) = INIT_DD 
 INIT_V = (RR0-1)*D/BETA 
 A_0(13) = INIT_V 
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$DES 
 
 DADT(1) = -KA1*A(1)   ; DEPOT COMPT FOR DRUG EFV 
 DADT(2) = -KA2*A(2)   ; DEPOT COMPT FOR DRUG FTC 
 DADT(3) = -KA3*A(3)   ; DEPOT COMPT FOR DRUG TDF 
 DADT(4) = KA1*A(1) - K1*A(4)  ; CENTRAL COMPT FOR DRUG EFV 
 DADT(5) = KA2*A(2) - KEFTC*A(5) - K12FTC*A(5) + K21FTC*A(7)  
  ; CENTRAL COMPT FOR DRUG FTC 
 DADT(6) = KA3*A(3) - KE*A(6) - K12*A(6) + K21*A(8)        
  ; CENTRAL COMPT FOR DRUG TDF 
 DADT(7) = K12FTC*A(5) -K21FTC*A(7)   
 ;PERIPHERAL COMPT FOR DRUG FTC 
 DADT(8) = K12*A(6)  - K21*A(8) 
  ; PERIPHERAL COMPT FOR DRUG TDF 
  
 EFV_CONC = A(4)/V1 
 FTC_CONC = A(5)/VC2 
 TDF_CONC = A(6)/VC3 
  
 INH_EFV = 1-1/(1 + (EFV_CONC**1/IC50EFV**2)) 
 INH_FTC_TDF = 1-1/(1 + (FTC_CONC/IC50FTC + TDF_CONC/IC50TDF)) 
 INH_TOTAL = INH_EFV*INH_FTC_TDF 
 
 
 DADT(9) = LABMDA - D*A(9) - (1-INH_TOTAL)*BETA*A(9)*A(13) 
 ; TARGET UNINFECTED CELL 
 DADT(10) = Q1*(1-INH_TOTAL)*BETA*A(9)*A(13) - AA1*A(10) + 
ALPHA*A(11)  ; ACTIVELY INFECTED CELL 
 DADT(11) = Q2*(1-INH_TOTAL)*BETA*A(9)*A(13) - AA2*A(11) - 
ALPHA*A(11) ; LATENTLY INFECTED CELL 
 DADT(12) = Q3*(1-INH_TOTAL)*BETA*A(9)*A(13) - AA3*A(12)  ; 
DEFECTIVELY INFECTED CELL 
  
 AI = A(10)  
 LI = A(11) 
 DI = A(12) 
  
  
 IF (A(10).LT.1) THEN 
 BETA=0 
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 ELSE 
 BETA = 2*(10**(-8)) 
 END IF    ; if actively infected cell < 1, then viral production rate, pp, is zero 
  
 DADT(13) = PP*A(10) - C*A(13)  ; VIRUS 
 
$ERROR 
 
  REPI=IREP ; simulation index 
 
  IPRED = 50    ; LLOQ is defined as 50 copies/mL 
  IF (A(10).GT.0) IPRED=A(13) ;DV is log10(VL in IU/L) 
   
  Y=50 
   
  IF (A(13).GT.50) Y=IPRED+EPS(1) 
   
$THETA 
 
 (252 FIX)       ; Vc for EFV  
 (9.4 FIX)      ; CL/F for EFV   
 (0.3 FIX)  ; KA for EFV   
  
 (0.97 FIX)   ; KA for FTC  
 (47 FIX )      ; Vc for FTC 
 (21 FIX)     ; CL for FTC   
 (16 FIX)     ; Q2 for FTC    
 (50 FIX)       ; Vp for FTC 
  
 (534 FIX)       ; Vc/F, L for TDF 
 (90.9 FIX)   ; CL/F, L/day for TDF   36.2+135*(BW/SCR) 
 ; we used mean values of BW and SCR, 66 kg and 83 uM, respectively 
 (144 FIX)    ; Q/F, L/hour => L/24h=L/day for TDF    
 (1530 FIX)      ; Vp/F, L for TDF  
  
  
 (0.2 FIX)      ; IC50 FOR EFV    0.00051 mg/L from Parkin, N.T. (2004) 
 (0.004 FIX)    ; IC50 for FTC   the value from Wang,L (2004)  
   ; package insert : 0.0003 ~ 0.158 mg/L 
 (0.025 FIX)    ; IC50 for TDF package insert EC50 : 0.02 ~ 5.4 mg/L 
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$OMEGA 
 (0.298 FIX) ; IIV on F1 for EFV 
 (0.372 FIX) ; IIV on Ka for FTC 
 (0.029 FIX) ; IIV on CL/F for FTC 
  
$OMEGA BLOCK(2) 
 (0.0654 FIX)   ;IIV on CL for TDF 
 (0.11 FIX)  ; Cov on Vc and CL 
 (0.37 FIX)     ; IIV on Vc for TDF 
 
$SIGMA 
 (0.01 FIX)   
 
$SIM (89234) ONLYSIMULATION NSUBPROBLEMS=1 
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III. Population PK model for pegylated-interferon α 2b based treatment 
(Chapter 3) 
 
$PROBLEM FINAL PK MODEL FOR PEG-INF 
$INPUT ID PID=DROP TIME EVID AMT DV MDV RACE HCV INFL FIBR 
GENO HIV CD4 WT OCC 
$DATA pkdata1234.csv  IGNORE=C 
$SUBROUTINE ADVAN2 TRANS2 
$PK 
 
WEEK1=0 
WEEK2=0 
 
 IF (OCC.EQ.1) THEN 
 WEEK1=1 
 ELSE 
 WEEK2=1 
 END IF 
 
 KA=THETA(1)*EXP(ETA(3)) 
 CL=THETA(2)*EXP(ETA(1)) 
 V=THETA(3)*EXP(ETA(2)+ETA(4)*WEEK1+ETA(5)*WEEK2) 
 S2=V 
 
$ERROR 
 
IPRED=F 
IRES = DV - IPRED  
  
DEL=0  
IF (F.EQ.0) DEL=0.001 
IWRES= IRES/(F+DEL) 
Y=F*(1+ERR(1)) 
 
$THETA 
(0, 1) ; KA 
(0, 22 ) ;CL/F 
(0, 0.4) ; V/F 
 
$OMEGA  
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0.04 
0.04 
0.04 
$OMEGA BLOCK(1) 0.04 
$OMEGA BLOCK(1) SAME 
 
$SIGMA  
0.01 
 
$ESTMETHOD METHOD=CONDITIONAL INTER  POSTHOC NSIG=4 
MSF=601.MSF 
 
$COVARIANCE PRINT=E UNCONDITIONAL 
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IV. Population PK-PD/HCV viral dynamic model for pegylated-interferon 
α 2b based treatment (Chapter 3) 
 
$PROB1 CHAPTER 3, FINAL POPULATION PK-PD/HCV MODEL 
;Units: Time (DAY) 
;PD Volume (mL) 
$DATA pkpd6.csv IGNORE='C' 
$INPUT PID=DROP ID TIME AMT EVID DV HCV MDV SKA SCL SV1 SV2 
RACE BSHCV INFL FIBR GENO BSHIV CD4 WT OCC RESP   
 
$SUBROUTINE ADVAN13 TOL=9 
$MODEL 
 
  COMP=(ABS,DEFDOSE) 
  COMP=(CENT) 
  COMP=(UCELL)  ;UNINFECTED CELLS 
  COMP=(ACELL)  ;INFECTED CELLS 
  COMP=(VIRUS, DEFOBS) 
  
$PK 
 
 IF (OCC.EQ.1) V2=SV1  
 IF (OCC.EQ.2) V2=SV2 
 S2=V2 
  
 KA=SKA ;per Day 
 CL=SCL ; 
 
  RR0 = THETA(1)    ; basic reproductive number before treatment 
  C = THETA(2)                  ; virion elimination rate constant (per day) 
DELTA= THETA(3)*EXP(ETA(2))     
    ; infected cell death rate constant ( per day) 
TVIC50 = THETA(4)+THETA(6)*(GENO-1)     
    ; 1 for genotype 1, 2 for non-genotype 1 
  IC50 = TVIC50*EXP(ETA(1))              ; IC50 of PEG-INF 
   
  GAMMA=THETA(5) 
 
  S=61.7*10**3   ; hepatocyte production rate (Hepatocytes/ml/DAY) 
  D=0.003    ; hepatocyte death rate constant 
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  LOGV0=BSHCV 
  V0=10**LOGV0 
  BETA=((RR0-1)/V0)*D 
 
 ;;;;;;;;;; initialize each compartment to pre-treatment equilibrium;;;;;;;;;;;;; 
 
INIT_MU=S/(D*RR0) 
A_0(3)=INIT_MU 
INIT_A=(S/DELTA)*(1-(1/RR0)) 
A_0(4)=INIT_A 
PP=V0*C/INIT_A 
INIT_V=(PP/C)*INIT_A 
A_0(5)=INIT_V 
 
$DES 
  
  DADT(1) = -KA*A(1)                  ;A(1) AMOUNT 
  DADT(2) = KA*A(1) - (CL/V2)*A(2)   ;A(2) AMOUNT 
  CONC=A(2)/V2 
 
  INH = CONC**GAMMA/(CONC**GAMMA+IC50**GAMMA) 
 
  DADT(3) = S-D*A(3)-BETA*A(5)*A(3)       ;uninfected hepatocyte 
  DADT(4) = BETA*A(5)*A(3) -DELTA*A(4)    ;infected hepatocyte 
  DADT(5) =(1-INH)*PP*A(4)-C*A(5)         ;virus  
  
$ERROR 
  IPRED = 0 
  IF (A(4).GT.0) IPRED=LOG10(A(5)) ;DV is log10(VL in IU/L) 
  W=1 
  IRES=DV-IPRED 
  IWRES=IRES/W 
  Y=IPRED+ERR(1) 
 
$THETA 
(1,5) ; R00 
(6.2 FIX) ; C 
(0,0.1) ; DELTA 
(0,0.02080) ; IC50 
(0,0.7 ); GAMMA 
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(0.5) ; THETA6 
 
$OMEGA      
6.330 ;IC50 
0.01 ; delta    
 
$SIGMA  0.2400     
 
$ESTIMATION MAXEVAL=9999 PRINT=10 SIG=3 METHOD=1 INTER 
NOABORT SIGL=9 NSIG=3 MSFO=INTERM.MSF  
$COV MATRIX=R PRINT=E UNCONDITIONAL 
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V. Population PK-PD/HCV viral dynamic model for Monte Carlo 
simulation for stochastic long-term clinical outcomes (Chapter 4) 
$PROB1 CHAPTER 4 
;Units: Time (DAY) 
;PD Volume (mL) 
$DATA HCV_sim2.csv IGNORE='C' 
$INPUT ID TIME WEEK EVID AMT ADDL II DV MDV RACE BSHCV 
INFL=DROP FIBR=DROP GENO BSHIV CD4 WT OCC RESP    
$SUBROUTINE ADVAN13 TOL=9 
 
$MODEL 
  COMP=(ABS,DEFDOSE) 
  COMP=(CENT) 
  COMP=(UCELL)    ;UNINFECTED CELLS 
  COMP=(ACELL)    ;INFECTED CELLS 
  COMP=(VIRUS, DEFOBS)   ;INFECTIOUS HCV VIRUS 
  COMP=(NVIRUS )   ;NON-INFECTIOUS HCV VIRUS 
 
$PK 
;;;;;;;;;;;;;;; PK model ;;;;;;;;;;;;;;;;;;; 
  
KA=THETA(1)*EXP(ETA(3)) 
 CL=THETA(2)*EXP(ETA(1)) 
 
 WEEK1=0 
 WEEK2=0 
 
 IF (WEEK.LE.1) WEEK1=1  
 IF (WEEK.GT.1.AND.WEEK.LE.2) WEEK2=1 
 
 V=THETA(3)*EXP(ETA(2)+ETA(4)*WEEK1+ETA(5)*WEEK2) 
 S2=V 
 
;;;;;;;;;;;;;;; PD model ;;;;;;;;;;;;;;;;;;; 
 
  ;;; PEG-INF drug effect parameters 
   
  IC50 = THETA(4)*EXP(ETA(6)) 
  GAMMA=THETA(5) 
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  ;;; RBV drug effect parameters 
   
  TA = 5.6      ; day, accumulation time scale 
  ROMAX = 0.5  ;  maximum RBV drug effect 
  
;;;;;;;;;;;;;;;; Disease model ;;;;;;;;;;;;; 
 
  RR0 = THETA(6)     ; basic reproductive number before treatment 
  C = THETA(7)                   ; virion elimination rate constant (per day) 
DELTA= THETA(8)*EXP(ETA(7))           
    ; infected cell death rate constant ( per day) 
  S=61.7*10**3  ; hepatocyte production rate (Hepatocytes/ml/DAY) 
  D=0.003   ; hepatocyte death rate constant 
 
  LOGV0=BSHCV 
  V0=10**LOGV0 
  BETA=((RR0-1)/V0)*D 
 
 ;;;;;;;;; initialize each compartment to pre-treatment equilibrium ;;;;;;;;;;;;;;;;;;;; 
 
INIT_MU=S/(D*RR0)                    ; target uninfected hepatocyte 
A_0(3)=INIT_MU 
INIT_A=(S/DELTA)*(1-(1/RR0))        ; infected hepatocyte 
A_0(4)=INIT_A 
PP2=V0*C/INIT_A 
INIT_VI=(PP2/C)*INIT_A               ; infectious HCV virus 
A_0(5)=INIT_VI 
INIT_VNI = 0                         ; non-infectious HCV virus 
A_0(6)=INIT_VNI 
  
$DES 
  DADT(1) = -KA*A(1)                ;A(1) AMOUNT 
  DADT(2) = KA*A(1) - (CL/V)*A(2)  ;A(2) AMOUNT 
  CONC=A(2)/V 
 
  IF(TIME.GT.336) THEN 
  CONC=0.001   
ELSE 
; PEG-INF drug effect 
INH = CONC**GAMMA/(CONC**GAMMA+IC50**GAMMA)       
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  ENDIF 
 
       ;336 days(48weeks) is end of treatment and 
  ;thus the concentration should be zero,  
       ;but we still measure viral-load during the next 24 weeks follow-up period 
 
  IF(TIME.GT.336) THEN  
  RO=0 
  ELSE 
  RO = ROMAX*(1-EXP(-TIME/TA))                    ;RBV drug effect 
  ENDIF 
 
  DADT(3) = S-D*A(3)-BETA*A(5)*A(3)       ;uninfected hepatocyte 
  DADT(4) = BETA*A(5)*A(3) -DELTA*A(4)    ;infected hepatocyte 
   
  IF (A(4).LT.1) THEN  
  PP=0  
  ELSE  
  PP=V0*C/INIT_A 
  ENDIF 
  
  DADT(5) = (1-INH)*PP*A(4)-C*A(5)        ; INFECTIOUS VIRUS  
  DADT(6) = RO*(1-INH)*PP*A(4) - C*A(6)    ; NON-INFECTIOUS VIRUS 
 
  IC = A(4)   ; infected cell 
  VI = A(5)   ; infectious virus 
  VNI = A(6)  ; non-infectious virus 
  VIRUS = VI + VNI 
  
 
$ERROR 
  IPRED = LOG10(29) 
IF (A(5)+A(6).GT.29) IPRED=LOG10(A(5)+A(6))   
  ; lower limit of detection of 29 IU/ml 
  Y=LOG10(29) 
  IF (A(5)+A(6).GT.29) Y=IPRED+ERR(1) 
  REPI = IREP 
 
$THETA 
(0.364 FIX)   ; KA 
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(39.8 FIX)    ; CL/F 
(25.9 FIX)     ; V/F 
(0.507 FIX)   ; IC50 FOR GENOTYPE1 
(2.97 FIX )  ; GAMMA 
(16.4 FIX)   ; R00 
(6.2 FIX)   ; C 
(0.402 FIX)   ; DELTA 
 
$OMEGA  
(0.08 FIX )     ; IIV CL 
(0.603 FIX)    ; 
(0.208 FIX)    ; IIVKA 
(0.191 FIX)    ; IOV of Vd week1 
(0.191 FIX)    ; IOV of Vd week2 
(0.381 FIX)   ;IIV ON IC50 FOR GENOTYPE 1 
(1.15  FIX)   ; delta    
 
$SIGMA  0.0801 FIX   
 
$SIM (12847583) ONLYSIMULATION NSUBPROBLEMS=1000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
B. BERKELEY MADONNA CODE 
 
i. PK-PD/HIV viral dynamic model used for the exploratory deterministic 
simulation in combination regimen of Atripla (Chapter 2) 
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=24*7   
DT = 0.02 
 
{EFV PK model, 1-compt, reference of Csajka C (2003)} 
 
 {multiple dosing} 
 Tau1=24 ; hours 
 InputRate1=DT 
 NumberOfDoses1=7 
 TimeOfFirstDose1=0 
 Dose1=600     ;dose: 600mg, concentration: mg 
 
 Dosing1[1..NumberOfDoses1] = squarepulse(TimeOfFirstDose1+(i-
1)*Tau1,InputRate1)/InputRate1 
 TotalDosingRate = Dose1*ARRAYSUM(Dosing1[*]) 
 
 {parameters} 
 V1=252                    ; L 
 CL1=9.4                   ;L/hour 
 KA1=0.3                  ; per hour 
 K1=CL1/V1 
 
 {initialise state variables} 
  init DepotCompartment1 =0 
 init CentralCompartment1=0 
 
 {differential equations} 
 d/dt(DepotCompartment1)=TotalDosingRate-KA1*DepotCompartment1 
 d/dt(CentralCompartment1)=KA1*DepotCompartment1-    
K1*CentralCompartment1 
  
 EFVconcentration=CentralCompartment1/V1 
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{FTC PK model, 2-compt, reference of Wang, L (2004)} 
 
 {multiple dosing} 
 Tau2=24 ; hours 
 InputRate2=DT 
 NumberOfDoses2=7 
 TimeOfFirstDose2=0 
 Dose2=200     ;dose: 200mg, concentration: mg 
 
 Dosing2[1..NumberOfDoses2] = squarepulse(TimeOfFirstDose2+(i-
1)*Tau2,InputRate2)/InputRate2 
 TotalDosingRate2 = Dose2*ARRAYSUM(Dosing2[*]) 
 
 {parameters} 
 KA2=0.97   ;0.53      ;hr 
 Vc2=47     ;    127                  ; L 
 CL2=21;    23.2                   ;L/hour 
 Q2=16  ; 6 
 Vp2=50;   237                   ; 
 KeFTC=CL2/Vc2 
 K12FTC=Q2/Vc2 
 K21FTC=Q2/Vp2 
 
 {initialise state variables} 
  init DepotCompartment2=0 
 init CentralCompartment2=0 
 init PeripheralCompartment2=0 
 
 {differential equations} 
 d/dt(DepotCompartment2) =  TotalDosingRate2-KA2*DepotCompartment2 
 d/dt(CentralCompartment2)=KA2*DepotCompartment2-
KeFTC*CentralCompartment2 - K12FTC*CentralCompartment2 + 
K21FTC*PeripheralCompartment2 
 d/dt(PeripheralCompartment2)=  K12FTC*CentralCompartment2 - 
K21FTC*PeripheralCompartment2 
 
 FTCconcentration=CentralCompartment2/Vc2  
 
{TDF PK model, 2 compt model, reference of Jullien V (2005)} 
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 {multiple dosing} 
 Tau3=24 ; hours 
 InputRate3=DT 
 NumberOfDoses3=7 
 TimeOfFirstDose3=0 
 Dose3=300     ;dose: 300mg, concentration: mg 
 
 Dosing3[1..NumberOfDoses3] = squarepulse(TimeOfFirstDose3+(i-
1)*Tau3,InputRate3)/InputRate3 
 TotalDosingRate3 = Dose3*ARRAYSUM(Dosing3[*]) 
 
 {parameters}  
 Vc3=534                 ; L 
 CL3=90.9                ;L/hour 
 Q3=144                   ;L/hour 
            Vp3=1530                ; L 
   Ke=CL3/Vc3 
 K12=Q3/Vc3 
 K21=Q3/Vp3 
 Ka3=Ke 
   
 {initialise state variables} 
  init DepotCompartment3 =0 
 init CentralCompartment3=0 
 init PeripheralCompartment3=0 
 
 {differential equations} 
 d/dt(DepotCompartment3)=TotalDosingRate3-Ka3*DepotCompartment3        
 d/dt(CentralCompartment3)=Ka3*DepotCompartment3-Ke*CentralCompartment3 
- K12*CentralCompartment3 + K21*PeripheralCompartment3 
 d/dt(PeripheralCompartment3)=  K12*CentralCompartment3 - 
K21*PeripheralCompartment3 
 
 TDFconcentration=CentralCompartment3/Vc3  
   
{PD model} 
 
 IC50EFV=  0.00051; 0.2   ;  0.00051                    ;;;  mg/L  Parkin, N.T. 
(2004) 
 INH_EFV=1-1/(1+(EFVconcentration/IC50EFV)) 
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 IC50FTC=    0.004                ;;; ug/ml=mg/L Wang, L (2004) 
 IC50TDF=0.025           ;;;mg/L;  IC50 of 2.3uM (from package insert) 
thus 2.3umol/L *635.53ug/umol=1.461 mg/L 
 INH_FTC_TDF=1-1/(1+(FTCconcentration/IC50FTC 
+TDFconcentration/IC50TDF)) 
 
 INH_total=INH_EFV*INH_FTC_TDF 
 
 EFV_IC50=EFVconcentration/IC50EFV 
 FTC_IC50=FTCconcentration/IC50FTC  
 TDF_IC50=TDFconcentration/IC50TDF 
 
{ HIV Viral Dynamic model including 4  
 T: target cell 
 A: actively infected cell 
 L: Latently infected cell 
 Dd: defectively infected cell 
 V: Virus 
} 
 
{parameters , values from a book Viral Dynamic (Martin A)} 
 d=0.1 ; death rate of target cell 
 labmda= 10**7  ; production rate of target cell  
 beta = 5*10**(-10)  ; infectivity rate 
 p = 500 ; viral production rate 
 c = 5    ;viral clearance rate 
 a1 = 0.5   ; death rate for actively infected cells 
 a2 = 0.01  ; death rate for actively latentaly cells 
 a3 = 0.008  ; death rate for defectively infected cells 
 q1 = 0.55  ; percentage being A cell 
 q2 = 0.05  ; percentage being L cell 
 q3 = 0.4    ;percentage being D cell 
 alpha = 0.4 
 
 R0= beta*labmda*p/(a1*d*c)*(q1 + q2*(alpha/(alpha+a2))) 
 
{initialise state variables} 
 INIT_T=labmda/(d*R0) 
 init T = INIT_T 
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 INIT_A = (R0 -1 )*d*c/(beta*p) 
 init A=INIT_A 
 INIT_L = INIT_A*(a1/q1)/((alpha+a2)/q2 + alpha/a1) 
 init L=INIT_L 
 init Dd= INIT_L*((alpha+a2)/q2) / (a3/q3) 
 init V = (R0 - 1)*d/beta 
 
{differential equations} 
 
 d/dt(T) = labmda - d*T - (1 - INH_total)*beta*T*V 
 d/dt(A) = q1*(1 - INH_total)*beta*T*V - a1*A + alpha*L 
 d/dt(L) = q2*(1 - INH_total)*beta*T*V - a2*L - alpha*L 
 d/dt(Dd) = q3*(1 - INH_total)*beta*T*V - a3*Dd 
 d/dt(V) = p*A - c*V 
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ii.PK-PD/HCV viral dynamic model for the exploratory deterministic 
simulation on HCV long-term clinical outcome (Chapter 4) 
METHOD RK4 
 
;; unit : day 
 
STARTTIME = 0 
STOPTIME= (48+24)*7     
  ;simulate HCV viral load 24 weeks after 48 week treatment 
DT = 0.02 
DTOUT = 7 ; output time interval 
 
{ PEG-INF 2b PK model, 1-compt } 
 
 Tau=7     ; weekly dosing 
 InputRate = DT 
 NumberOfDoses = 48 ; weekly dosing for 48 weeks 
 TimeOfFirstDose = 0 
 weight = 82    ; the average weight for the population, unit - kg 
 Dose= 1.5*weight   ; 1.5ug/weight adjusted dose 
 
 Dosing[1..NumberOfDoses] =squarepulse(TimeOfFirstDose + (i-1)*Tau, 
InputRate)/InputRate 
  
 TotalDosingRate = Dose*ARRAYSUM(Dosing[*]) 
 
 {parameters} 
  Ka = 0.36 ;day-1 
  CL = 39.8 ;L/day 
  Vd = 25.9  ;L 
  K = CL/Vd 
 
 {initialize state variables} 
 init DepotCompartment = 0 
 init CentralCompartment = 0 
 
 {Differential equations} 
 d/dt (DepotCompartment) = TotalDosingRate - Ka*DepotCompartment 
 d/dt (CentralCompartment) = Ka*DepotCompartment - K*CentralCompartment 
 
 INFconcentration = CentralCompartment/Vd 
 
 {PD function} 
  
 {parameters} 
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 IC50=0.508 
 slope= 2.79 
 
 ta = 5.6   ; ribavirin accumulation time scale 
 ROmax = 0.5 ; maximum inhibiton by ribavirin 
 
 IC50coverage = INFconcentration/IC50 
 
 INH = INFconcentration**slope/(INFconcentration**slope + IC50**slope) 
 RO = ROmax*(1-exp(-time/ta)) 
 
{HCV viral dynamic model} 
 
 {parameters} 
 S = 61.7*10**3  ;production rate of uninfected cell 
 d = 0.003   ;dealth rate of uninfected cell 
 c = 6.2    ; viral clearance rate 
 delta = 0.425   ; death rate of infected cell 
 V0 = 10**(6.1)  ;baseline HCV 
 R0 = 12.4    ;basic reproductive ratio 
 BETA=((R0-1)/V0)*d 
 
 
 {initialize state variable before treatment} 
 INIT_T = S/(d*R0)    ; target uninfected cell 
 init T = INIT_T 
 INIT_A = (S/delta)*(1-(1/R0)) ;infected cell 
 init A = INIT_A 
 p=V0*c/INIT_A   ; viral production rate 
 INIT_Vi =(p/c)*INIT_A 
 init Vi = INIT_Vi   ;infectious virus 
 init Vni = 0                        ; non-infectious virus  
 
 {Differential Equation} 
 d/dt (T) = S-d*T - BETA*Vi*T   ; uninfected hepatocyte 
 d/dt (A) = BETA*Vi*T - delta*A   ; infected hepatocyte 
          
 p= IF A <= 1  THEN  0 ELSE V0*c/INIT_A            
   ; if infected cell is less than 1, p set to 0 
 
 d/dt (Vi) = (1-RO)*(1-INH)*p*A - c*Vi  ; infectious HCV virus 
 d/dt (Vni) = RO*(1-INH)*p*A - c*Vni  ; non-infectious virus 
   
 virus = Vi + Vni 
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C. R CODE 
 
i. Simulation of non-compliance pattern for Atripla using a 2-state Markov 
model 
 
# < pattern 1> : simulates variable timing in dose intake of QD combination of 
#                       EFV+FTC+TDF 
# Time period of study, T = 10 weeks = 70 days 
 
con = data.frame(interval=rep(1,32)) 
set.seed(2312) 
    
interval=rnorm((70-32),1,0.1)     
ran = data.frame(interval)  # the number of dosing prescired in random time is 65,  
           # dosing interval 24 hour, SD of timing error=12 hour  
df1 = rbind(con,ran) 
df1$presTIME <- seq(0,69,1) 
df1$DAY <-0 
for (i in 2:length(df1$interval) ) 
{ 
  df1$DAY[i] <- df1$interval[i]+df1$DAY[i-1] 
} 
 
## scatter plot of prescribed time vs.  dose interval or actual time drugs took 
par(mfrow=c(1,2), mar=c(5,4,4,2), oma=c(0.5,1,0.5,1), cex.axis=1.5) 
plot(df1$presTIME, (df1$interval*24),xlab="",ylab="", pch=19) 
mtext("Prescribed time (Day)", side=1, line=3, cex=1.3) 
mtext("Dose interval (Hour)", side=2, line=3, cex=1.3) 
abline(24,0,lty=3, lwd=2, col="blue") 
plot(df1$presTIME, df1$DAY,xlab="", ylab="",pch=19, xlim=c(0,72),ylim=c(0,72) ) 
mtext("Prescribed time (Day)", side=1, line=3, cex=1.3) 
mtext("Actual time drugs took (Day)", side=2, line=3, cex=1.3) 
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abline(0,1,lty=1, lwd=2, col="blue") 
#END of scatter plots 
 
histogram(df1$interval, xlab = "Dosing interval (h)",ylab = "Density of probability", 
            type = "density",probability=T,nint = 50,xlim=c(-2,70)) 
             
# < pattern 2 > Markov model of medication compliance 
# markov model to describe compensation of missing dose and 
# increasd probability of missing a dose if the previous odse was also not taken 
 
Markov <- function(L,p00,p11) 
{ 
  p01 <- 1-p00 
  p10 <- 1-p11 
  set.seed(69289) 
  NT <-sample(c(-1,1),size=L,replace=T,prob=c(p00,p01)) 
  T <- sample(c(-1,1),size=L,replace=T,prob=c(p10,p11)) 
  Y <- rep(1,L) 
      for(i in 2:L) { 
        if(Y[i-1]==-1) Y[i] <- NT[i] 
          else Y[i] <- T[i] 
        } 
      Y 
} 
 
Y <- Markov(70,0.6,0.8) 
Y 
 
df2 = rbind(con,ran) 
df2$presTIME <- seq(0,69,1) 
df2$DAY <-0 
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for (i in 2:length(df2$interval) ) 
{ 
  df2$DAY[i] <- df2$interval[i]+df2$DAY[i-1] 
} 
df2$dose <- 3  # becaseu patients who took drugs were tood as one oral tablet for 
EFV + FTC +TDF 
df2$dose <-ifelse(Y==-1,0,df2$dose) 
df2$DAY2 <- df2$DAY*df2$dose 
df3=subset(df2,df2$DAY2!=0) 
df3$DAY2 <-c(0,df3$DAY[-nrow(df3)]) 
df3$interval <- df3$DAY-df3$DAY2 
 
## scatter plot of prescribed time vs.  dose interval or actual time drugs took for 
pattern 2 
par(mfrow=c(3,1), mar=c(2.5,4,2.5,2), oma=c(3,1,0.5,1), cex.axis=1.9) 
plot(df3$presTIME, (df3$interval),xlab="",ylab="", pch=19) 
mtext("Prescribed time (Day)", side=1, line=3, cex=1.2) 
mtext("Dose interval (Day)", side=2, line=3, cex=1.2) 
abline(1,0,lty=3, lwd=2, col="black") 
 
plot(df3$presTIME, df3$DAY2,xlab="", ylab="",pch=19, xlim=c(0,72),ylim=c(0,72) ) 
mtext("Prescribed time (Day)", side=1, line=3, cex=1.2) 
mtext("Actual time drugs took (Day)", side=2, line=3, cex=1.2) 
abline(0,1,lty=1, lwd=2, col="black") 
 
plot(df3$DAY2,df3$dose, type='n',xlab = "",ylab = "",ylim=c(0,5)) 
segments(df3$DAY2,0,df3$DAY2,df3$dose,col = "black", lwd=3) 
mtext("Actual time drugs took (Day)", side=1, line=3, cex=1.2) 
mtext("The number of doses", side=2, line=3, cex=1.2) 
#END of scatter plots 
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####### creating  dosing records for Atripla, one tablet of (EFV+FTC+TDF) 
 id=seq(1,1000)   # 10 subjects 
 num_drugs = 3 
 Time <- df3$DAY2*24 
 three.dosing.time <- rep(Time, num_drugs)    # dosing times for 3 drugs     
dosing.time=300 of zeros 
 dosing.time <- three.dosing.time[order(three.dosing.time)] 
 
 dose.id = rep(id,length(dosing.time)) 
 dose.id = dose.id[order(dose.id)] 
 
 dosing <- data.frame(ID= dose.id,DRUG=rep(c(1,2,3),(length(id)*length(Time))), 
              TIME=rep(dosing.time,length(id)), 
              EVID = rep(c(1,1,1),length(id)*length(Time)),AMT= 
rep(c(600,200,300),length(id)*length(Time)), 
              CMT = rep(c(1,2,3),length(id)*length(Time)), DV = 
rep(c(0,0,0),length(id)*length(Time)), 
              MDV = rep(c(1,1,1),length(id)*length(Time))             
              )    
             
####### creating  observation records for viral loads 
 
  id=seq(1,1000) 
  obs.hour <-  c(seq(0,7*24,by=24),seq(8*24,10*7*24,24))  # clinical evaluation for 
efficacy is usually perfomed at baseline and at weeks 4, 12, 24, 36 and 48.  
  obs.hour[1] <- 1 
   
  obs.id = rep(id,length(obs.hour)) 
obs.id = obs.id[order(obs.id)] 
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  obs <- data.frame(ID= obs.id, DRUG=rep(0,length(obs.hour)*length(id)),TIME = 
rep(obs.hour,length(id)), EVID = rep(0,length(obs.hour)*length(id)), 
                    AMT = rep(0,length(obs.hour)*length(id)),  
                    CMT = rep(13, length(obs.hour)*length(id)),DV = 
rep(0,length(obs.hour)*length(id)),MDV = rep(0,length(obs.hour)*length(id)) 
                    ) 
 
   combination.data <- rbind(dosing,obs) 
   combination.data <- 
combination.data[order(combination.data$ID,combination.data$TIME,combination.
data$EVID),] 
 
write.csv(combination.data, file="VLdata_drugHolidays2.csv", 
sep=",",row.names=F, quote=F)       
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